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ABSTRACT 
 
S100A1 and S100B:  Novel Drug Targets for Alzheimer’s Disease Therapy. 
(December 2011) 
Emily Anna Roltsch, B.S.; M.S, Texas A&M University 
Chair of Advisory Committee: Dr. Danna B. Zimmer 
 
Numerous factors/gene products, including S100A1 and S100B, have been 
implicated in the onset and progression of Alzheimer’s disease (AD).   However, 
deciphering S100A1/S100B’s role in AD has been hampered by their antipodal effects 
and ability to act as both intracellular calcium receptors and secreted neuropeptides.  
This study utilizes two approaches, genetic ablation and passive immunotherapy, to 
inhibit S100A1 and/or S100B in the PSAPP AD mouse model to ascertain the net 
contribution of these proteins to AD pathology.  In addition, a combination of 
microarray profiling, post-array validation and bioinformatics were used to identify 
changes in miRNA expression in response to S100A1/S100B ablation.  In 6 month old 
mice, S100B ablation resulted in a 3-fold decrease in cortical but not hippocampal 
plaque load while S100A1 ablation resulted in a 3.5-fold reduction in cortical and a 2.4-
fold reduction in hippocampal plaque load.  Interestingly, ablation of both S100A1 and 
S100B was synergistic resulting in an age-, region- and end point- specific manner.  
Diminished plaque load was accompanied by decreased GFAP-positive astrocytes and 
Iba-1 positive microglia.  The effects of S100A1/S100B on plaque load were not limited 
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to early stages of plaque deposition.  Even though older (12 month old) PSAPP animals 
had over 6-fold increase in plaque load, S100A1 or S100A1/S100B ablation still 
diminished cortical/hippocampal plaque load by 60-65%.  Similar results were observed 
when passive immunotherapy was used to inhibit S100A1/S100B function.  Anti-S100 
treatment of mice from 3-6 months of age decreased cortical/hippocampal plaque load, 
and decreased cortical but not hippocampal GFAP staining.  The effects of passive 
immunotherapy with S100A1/S100B antibodies were not limited to pre-plaque 
treatment.  Anti-S100 treated mice from 6-9 months of age exhibited decreased cortical, 
but not hippocampal, plaque load and cortical/hippocampal GFAP staining.  In addition, 
these S100A1/S100B mediated decreases were accompanied by downregulated 
expression of miR- 448, miR-133a, miR-204, and miR-206 as well as upregulated 
expression of miR-34a.  Collectively, these data demonstrate that inhibition of S100A1 
and S100B synergistically reduce AD pathology and suggest that the detrimental gain of 
function of S100A1/S100B contributes to AD.  Therefore, development of drugs to 
inhibit S100 function in patients will be beneficial in the treatment of AD and slowing 
disease progression.  
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NOMENCLATURE 
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AD Alzheimer’s Disease 
APP Amyloid Precursor Protein 
BACE1 β-site of APP Cleaving Enzyme 
BDNF Brain-Derived Neurotrophic Factor 
BP Base Pair 
Ca2+ Calcium 
CDK5 Cyclin-Dependent Kinase 5 
CNS Central Nervous System 
CX Cortex 
CR Cerebellum 
DAPI 4’,6-diamidino-2-phenylindole 
GFAP Glial Fibrillary Acidic Protein 
GSK3β Glycogen Synthase Kinase 3 Beta 
HCV Hepatitis C Virus 
HP Hippocampus 
IBA1 Ionized Calcium Binding Adaptor Molecule 1 
IFNβ Interferon β 
KLF5 Kruppel-like Factor 5 
miRNA Micro-ribonucleic Acid 
 viii
miR- Micro-ribonucleic Acid 
mESC Mouse Embryonic Stem Cells 
NaCl Sodium Chloride 
NaOH Sodium Hydroxide 
NF-κB Nuclear Factor Kappa-light-chain-enhancer of Activated B Cells 
NIH National Institutes of Health 
OLF Olfactory Bulb 
PBS Phosphate Buffered Saline 
PCR Polymerase Chain Reaction 
PKA Protein Kinase A 
Pre-miRNA Precursor Micro-ribonucleic Acid 
Pri-miRNA Primary Micro-ribonucleic Acid 
PSEN1 Presenilin 1 Gene 
PS-1 Presenilin 1 
PSEN2 Presenilin 2 Gene 
RNA Ribonucleic Acid 
SATB1 Special AT-rich Sequence-binding Protein-1 
SEM Standard Error of the Mean  
UTR Untranslated Region 
 ix
TABLE OF CONTENTS 
 
              Page 
ABSTRACT ..............................................................................................................  iii 
DEDICATION ..........................................................................................................  v 
ACKNOWLEDGEMENTS ......................................................................................  vi 
NOMENCLATURE ..................................................................................................  vii 
TABLE OF CONTENTS ..........................................................................................  ix 
LIST OF FIGURES ...................................................................................................  xii 
LIST OF TABLES ....................................................................................................  xiv 
CHAPTER 
 I INTRODUCTION ................................................................................  1 
 
 II PSAPP MICE EXHIBIT REGIONALLY SELECTIVE  
  DECREASES IN GLIOSIS AND PLAQUE DEPOSITION  
  IN RESPONSE TO S100B ABLATION .............................................  14 
 
   Background ....................................................................................  14 
   Methods ..........................................................................................  18 
   PSAPP X S100B knockout mice ..............................................  18 
   Sample acquisition/processing .................................................  19 
   Immunohistochemical and Congo red staining ........................  19 
   Results ............................................................................................  21 
   S100B ablation reduces cortical, but not hippocampal, 
   plaque load ...............................................................................  21 
   S100B ablation reduces cortical, but not hippocampal, 
   gliosis .......................................................................................  23 
   Effects of S100B ablation on dystrophic neurons ....................  26 
   S100B colocalizes with hippocampal as well as cortical  
   astrocytes, microglia and plaques .............................................  27 
  Discussion ......................................................................................  30 
  Conclusions ....................................................................................  34 
 
 x
CHAPTER                  Page 
III S100A1 ABLATION REDUCES ALZHEIMER’S DISEASE 
PATHOLOGY IN THE PSAPP AD MOUSE MODEL ......................       35 
 
  Background ....................................................................................       35 
   Methods ..........................................................................................       38 
   PSAPP X S100A1 knockout mice ...........................................       38 
   Sample acquisition/processing .................................................       39  
   Immunohistochemical and Congo red staining ........................       39 
   Results ............................................................................................       40 
Mouse and human AD brain specimens contain S100A1 ........       40 
   S100A1 ablation decreases plaque load in PSAPP mice .........       43 
   S100A1 ablation reduces gliosis in the PSAPP AD mouse  
   model  .......................................................................................       45 
   S100A1 and S100B ablation synergistically reduce plaque  
   load and inflammation  .............................................................       50 
  Discussion ......................................................................................       52 
  Conclusions ....................................................................................       56 
 
IV PSAPP MICE EXHIBIT REDUCTIONS IN PLAQUE LOAD AND 
GLIOSIS IN RESPONSE TO S100A1/S100B INHIBITION WITH 
PASSIVE IMMUNOTHERAPY .........................................................       57 
                        
                  Background ....................................................................................       57 
   Methods ..........................................................................................       60 
   PSAPP mice .............................................................................       60 
   Chronic immunotherapy treatment ...........................................       61
   Sample acquisition/processing .................................................       61 
   Immunofluorescent and Thioflavin S staining .........................       62 
   Results ............................................................................................       63 
Anti-S100 therapy selectively reduces cortical and hippo- 
campal plaque load in PSAPP mice .........................................       63 
   Anti-S100 therapy selectively reduces astrocytosis in PSAPP 
   mice ..........................................................................................       66 
  Discussion ......................................................................................       68 
  Conclusions ....................................................................................       70 
 
 V MiRNA EXPRESSION IS ALTERED IN RESPONSE TO  
  S100A1/S100B MEDIATED REVERSAL OF AD PATHOLOGY ...       71 
                        
                  Background ....................................................................................       71 
 
 xi
CHAPTER                  Page 
   Methods ..........................................................................................       73 
   PSAPP X S100 knockout mice ................................................       73 
   MiRNA profiling ......................................................................       74 
   Post-array validation ................................................................       74 
   Bioinformatic searches .............................................................       75 
   Results ............................................................................................       75 
S100A1/S100B ablation normalizes miRNA expression .........       75 
   Functional analysis of miRNA target genes/pathways ............       77 
  Discussion ......................................................................................       80 
  Conclusions ....................................................................................       86 
 
 VI CONCLUSIONS ..................................................................................       87 
 
REFERENCES ..........................................................................................................       90 
VITA .........................................................................................................................     120 
 xii
LIST OF FIGURES 
 
FIGURE                                                                                                                        Page 
 1 Ca2+ dependent S100 protein function .......................................................  2 
 
 2 Alzheimer’s disease in the United States ...................................................  5 
 
 3 Alzheimer’s disease in the brain ................................................................  7 
 
 4  Histopathological development of Alzheimer’s disease ............................  8 
 
 5 The double transgenic PSAPP mouse model for AD .................................  11 
 
 6 Development of the PSAPP/S100 knockout mouse models ......................  13 
 
 7 S100B ablation reduces cortical, but not hippocampal plaque load...........  22 
 
 8 S100B ablation reduces cortical microgliosis ............................................  24 
 
 9 S100B ablation reduces cortical astrocytosis .............................................  25 
 
 10 S100B ablation reduces cortical phospho-tau staining ..............................  27 
 
 11 S100B distribution in PSAPP mice ............................................................  28 
 
 12 S100B staining co-localizes with plaques, microglia and astrocytes .........  30 
 
 13 S100A1 distribution in PSAPP mice ..........................................................  41 
 
 14 S100A1 distribution in human AD specimen ............................................  42 
 
 15 S100A1 ablation reduces cortical and hippocampal plaque load in six  
  month old PSAPP mice ..............................................................................  44 
 
 16 S100A1 ablation reduces cortical and hippocampal plaque load in  
  twelve month old PSAPP mice ..................................................................  46 
 
 17 S100A1 ablation reduces astrocytosis ........................................................  48 
 
 18 S100A1 ablation reduces microgliosis .......................................................  49 
 
 xiii
FIGURE                                                                                                                        Page 
 19 Timeline for anti-S100 immunotherapy treatment .....................................      61 
 
 20 Anti-S100 therapy reduces cortical and hippocampal plaque load with 
treatment at 3-6 months of age ...................................................................      64 
 
 21 Anti-S100 therapy reduces cortical but not hippocampal plaque load  
  with treatment at 6-9 months of age ...........................................................  65 
 
 22 Anti-S100 therapy reduces cortical but not hippocampal astrocytosis  
  with treatment at 3-6 months of age ...........................................................  66 
 
 23 Anti-S100 therapy reduces cortical and hippocampal astrocytosis with   
treatment at 6-9 months of age ...................................................................  67 
 
 24 S100A1 and S100B ablation normalize miRNA expression profile ..........  76 
 
 25 RT-PCR validation of altered miRNAs .....................................................  77 
 
 26 S100A1 and S100B in AD .........................................................................  88 
 xiv
LIST OF TABLES 
 
TABLE                                                                                                                          Page 
 
 1 FDA approved drugs for Alzheimer’s disease ...........................................  6 
 
 2 S100A1 and S100B ablation synergistically reduce plaque load and  
  microgliosis in six month old PSAPP mice ...............................................  50 
 
 3 S100A1 and S100B ablation synergistically reduce cortical astrocytosis in 
twelve month old PSAPP mice ..................................................................  51 
 
 4 Target and pathway predictions for miRs -448, -204, -133a and -206 ......  78 
 
 5 Target and pathway predictions for miR-34a .............................................  80 
 
 6 Target and pathway predictions for validated miRNAs .............................  81 
 
 
 1
CHAPTER I 
INTRODUCTION  
 
Calcium (Ca2+) signaling is responsible for a multitude of cellular functions, 
including gene expression, cell growth, development, survival and ultimately cell death.  
In neuronal cells, an increase in intracellular calcium [Ca2+]i levels triggers vesicle 
fusion and neurotransmitter release (Berridge, 1998).  Ca2+ receptor proteins convert 
changes in [Ca2+]i into responses.  Members of the S100/calmodulin/troponin 
superfamily of Ca2+ receptor proteins contain a highly conserved 12 amino acid EF-hand 
Ca2+ binding domain.  S100 proteins also contain a Ca2+ binding loop comprised of 14 
amino acids called the ‘pseudo EF-hand’ (Marenholz, et al., 2004; Zimmer, et al., 2005).  
Like all Ca2+ receptor proteins, S100 proteins undergo a conformational change after 
binding Ca2+, exposing a hydrophobic patch necessary for interacting with numerous 
intra- and extra-cellular protein targets and the subsequent exertion of their biological 
effects (Figure 1) (Marenholz, et al., 2004; Zimmer, et al., 2003; Zimmer, et al., 2005; 
Zimmer and Weber, 2010). 
 The first S100 family members were isolated as a brain-specific fraction in 1965 
and called S100 to denote their solubility in 100% saturated ammonium sulfate (Moore, 
1965).  This original fraction was composed of two 10,000 molecular weight proteins,  
 
 
____________ 
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S100A1 and S100B (Marenholz, et al., 2004; Zimmer, et al., 1995; Zimmer, et al., 
2005).  A total of 21 S100 proteins are encoded in the human genome, seventeen 
(S100A1-S100A16) of which are encoded in a gene cluster on human chromosome 
1q21.  The remaining family members are encoded on other chromosomes: S100B 
 
 
 
Biological Effect
Cellular Processes
Tau
GFAP
p53
Synapsin
Ca2+ homeostasis
Cell proliferation
Sensitivity to the toxic A peptide
Figure 1.  Ca2+ dependent S100 protein function. Red/blue denote the monomers of S100 protein with 
regions (yellow) denoting residues of the S100 dimer that bind target proteins (green).  On the right are 
examples of AD related target proteins, cellular processes and biological effects that S100 proteins are 
involved in.  (Zimmer and Weber, 2010)    
 
(human chromosome 21q22), S100G (human chromosome Xp22), S100P (human 
chromosome 4p16), S100Z (human chromosome 5q13).  Interestingly, the mouse 
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genome contains a region on chromosome 3 syntenic to the human cluster on 
chromosome 1q21 and lacks only 3 family members, S100A7, S100A12 and S100P 
(Marenholz, et al., 2004; Marenholz, et al., 2006; Wright, et al., 2009).   Each S100 
family member exhibits a unique cell-type specific expression pattern.  For example, ten 
family members are expressed in the brain:  S100A1, S100A2, S100A4, S100A5, 
S100A6, S100A10, S100A11, S100A13, S100B and S100Z (Zimmer, et al., 2005).  Of 
these, S100A1 and S100B exhibit the highest levels of expression.  Over 20 intracellular 
targets have been reported for S100A1/S100B.  In addition, S100A1 and S100B regulate 
a large number of diverse cellular processes including energy metabolism, cell 
proliferation and differentiation, cytoskeletal organization, Ca2+ homeostasis and signal 
transduction pathways (Donato, 2001; Heizmann and Cox, 1998; Roltsch, et al., 2010; 
Santamaria-Kisiel, et al., 2006).       
 S100B is reported to localize to several cell structure elements, in fact,  S100B is 
found dispersed throughout the cytoplasm and associated with microtubules, type III 
filaments and intracellular membranes (Sorci, et al., 2010).  In vitro studies on S100B 
have been conducted in several cell lines.  A recent study reports that PC12 cells over 
expressing S100B exhibit enhanced cell proliferation, as well as reduced apoptosis and 
sensitivity to nerve growth factor (NGF) when compared to control PC12 cells (Arcuri, 
et al., 2005).  In addition, it was reported that astrocytes with reduced S100B expression 
exhibited a decrease in cell proliferation and migration in addition to the acquisition of a 
differentiating phenotype when compared to control astrocytes (Brozzi, et al., 2009).    
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Within the cell, S100B regulates movement and cytoskeletal organization, cell 
proliferation, differentiation and cell signaling (Donato, et al., 2009).   
 S100B functions not only as an intracellular regulator, but as an extracellular 
peptide as well.  S100B release/secretion by astrocytes is regulated by forskolin, 
lysophosphatidic acid, serotonin, glutamate, IL-6β, metabolites and the neurotoxic 
amyloid beta (Aβ) peptide (Pena, et al., 1995; Pinto, et al., 2000; Quincozes-Santos, et 
al., 2010; Tramontina, et al., 2006; Whitaker-Azmitia, et al., 1990).  Extracellular S100B 
levels are also gender-, age- and concentration-dependent (Hu, et al., 1996; Leclerc, et 
al., 2010; Nogueira, et al., 2009).  Nanomolar S100B levels beneficially promote 
neuronal survival while micromolar levels detrimentally promote apoptosis (Hu, et al., 
1996).  These effects are thought to be mediated mostly, but not exclusively, by the 
receptor for advanced glycation end products (RAGE) (Hofmann, et al., 1999; Leclerc, 
et al., 2010; Sorci, et al., 2010).  
 Reports linking S100A1 with neuronal cell differentiation and function have 
renewed interest in S100A1 function in the brain (Zimmer and Landar, 1995).  Recent 
studies have reported that S100A1 colocalizes with synapsin I, one of its many target 
proteins, suggesting a role in vesicle trafficking (Benfenati, et al., 2004).  In vitro studies 
in PC12 cells have reported that S100A1 is up-regulated in response to NGF suggesting 
that S100A1 has a role in neuronal cell differentiation (Zimmer and Landar, 1995).  It 
has also been reported that S100A1 ablation in PC12 cells results in increased levels of 
soluble and polymerized tubulin, decreased proliferation, increased neurite extension 
(length and number), increased resistance to Aβ-induced cell death, stabilization of 
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intracellular Ca2+ levels and downregulation of amyloid precursor protein (APP) 
expression (Zimmer, et al., 1998; Zimmer, et al., 2005).  Collectively, these studies 
indicate S100A1 links cytoskeletal organization, proliferation and differentiation.  
Numerous neurological diseases have been associated with altered expression and/or 
function of S100A1 including multiple sclerosis, amyotrophic lateral sclerosis, and 
Alzheimer’s disease (AD) (Verma, et al., 2007; Zimmer, et al., 2005).  
 
Figure 2.  Alzheimer’s disease in the United States. Statistics about the population and the cost of Alzheimer’s 
disease in the US from 2010 (Alzheimer’s Association, et al., 2011).      
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Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the 
sixth leading cause of death in the United States (Alzheimer’s Association, 2011).  Over 
35 million people worldwide, 5.4 million in the United States alone, have been 
diagnosed with AD costing the country an estimated $183 billion annually in health care 
costs.  In addition, there are over 14 million unpaid care givers that provided 17 billion 
 6
hours of unpaid care in 2010, valued at $202 billion (Figure 2).  By mid-century, the 
number of individuals in the United States diagnosed with AD is projected to reach 11-
16 million and the annual cost of health care will reach $1.1 trillion.  Currently, there are 
no treatments available to slow or stop the progression of AD.  The five FDA-approved 
drugs available (Table 1) “temporarily slow worsening of symptoms for about six to 12 
months, on average, for about half the individuals that take them” (Alzheimer’s 
Association, et al., 2011).  The identification of a therapy that will slow the progression 
of AD is significant because even a one year delay in onset will reduce health care costs 
by $250 billion/year (Alzheimer’s Association, et al., 2011).   
 
Drug Name
(generic) Type Use Side Effects
Cognex
(tacrine)
Cholinesterase
inhibitor
Rarely prescribed due to 
safety concerns
Razadyne
(galantamine)
Cholinesterase
inhibitor
Symptomatic treatment 
for mild to moderate AD
Nausea, vomiting, diarrhea, weight loss, 
loss of appetite
Exelon
(rivastigmine)
Cholinesterase
inhibitor
Symptomatic treatment 
for mild to moderate AD
Nausea, vomiting, diarrhea, weight loss, 
loss of appetite, muscle weakness
Aricept
(donepezil)
Cholinesterase
inhibitor
Symptomatic treatment 
for mild to moderate AD Nausea, vomiting, diarrhea
Namenda
(memantine)
N-methyl D-
aspartate (NMDA) 
antagonist
Symptomatic treatment 
for moderate to severe AD
Dizziness, headache, constipation, 
confusion
Table 1.  FDA approved drugs for Alzheimer’s disease  
 
 
The most common, or “hallmark”, pathological features of AD are extracellular 
senile plaques, comprised primarily of misfolded amyloid beta (Aβ) peptides, 
intracellular neurofibrillary tangles (NFTs), comprised of hyperphosphorylated tau 
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protein and brain atrophy resulting from neuronal and dendritic loss (Figure 3) 
(Castellani, et al., 2010; Querfurth and LaFerla, 2010).  AD presents in one of two 
forms, sporadic or familial AD, which are clinically indistinguishable, differing only in 
their ages of onset (Reitz, et al., 2011).  We do not know the cause of sporadic AD, 
although it is believed that a combination of environmental and genetic risk factors exist,  
 
 
Figure 3.  Alzheimer’s disease in the brain. Image depicts a normal age matched brain section on the left and an 
Alzheimer’s disease brain section on the right.  In Alzheimer’s disease, protein mishandling causes a buildup of 
extracellular senile plaques comprised of Amyloid β (Aβ), intracellular neurofibrillary tangles form with in the 
neurons due to hyperphosphorylation of the Tau protein and resulting neuronal cell loss causes brain atrophy.
(Alzheimer’s Association, et al., 2011)  
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such as cardiovascular disease, elevated blood pressure, type 2 diabetes, smoking, 
history of depression, traumatic brain injury and the APOE ε4 gene allele (Castellani, et 
al., 2010; Reitz, et al., 2011).  Over 95% of AD cases are of the sporadic, or late onset 
form, that presents in patients >65 years old, while 1-5% are of the familial, or early 
onset form, that presents as early as 30 years old (Bekris, et al., 2010; Reitz, et al., 2011).  
Early-onset AD is hereditary and associated with known mutations in several genes, 
namely APP, PSEN1 and PSEN2 (Bertram, et al., 2010).  The APP gene encodes the 
Amyloid Precursor Protein (APP) which is cleaved to produce Aβ peptides and the 
presenilin genes (PSEN1 and PSEN2) encode proteins that are involved in APP 
breakdown and Aβ generation (Bekris, et al., 2010; Reitz, et al., 2011).  The clinical  
 
Figure 4.  Histopathological development of Alzheimer’s disease. Depicted above is the progression of AD 
pathobiology in both forms, sporadic (early) and familial (late) onset AD.  
Sporadic AD
 Environment
 Genetics
Destabilization of Ca2+ homeostasis
Tau 
phosphorylation Tangles
Familial AD
 PS1 mutations
 PS2 mutations
 APP mutations
Altered APP 
Processing Increased Aβ levels
 Plaques
Dementia
Downstream Effects
 Inflammation
 Neuronal cell 
death
 
 9
presentation and pathology of both forms include initial disturbances in Ca2+ 
homeostasis.  The altered APP processing caused by the genetic mutations in early-onset 
AD causes a remodeling of the Ca2+ signaling pathways (Berridge, 2010; 2011).  In both 
forms, dysregulated Ca2+ homeostasis is followed by inflammation, neurodegeneration, 
senile plaque deposition comprised of Aβ peptide, intracellular hyperphosphorylated tau 
and ultimately cognitive dysfunction (Figure 4) (Berridge, 2010; 2011; Demuro, et al., 
2010; Querfurth and LaFerla, 2010; Supnet and Bezprozvanny, 2010). 
Inflammation is an early and critical event in the pathology of AD.  The 
inflammatory response in the brain includes activation of microglia, astrocytes, 
macrophages and lymphocytes that results in the release of inflammatory mediators that 
further recruit immune cells through the blood brain barrier (BBB) as well as additional 
microglia (Cameron and Landreth, 2010; Lee, et al., 2010).  Activated microglia 
overexpress interleukin 1β (IL-1β) leading to the production of APP by neurons and 
subsequent activation of astrocytes, which overexpress S100B and leads to increased 
Ca2+ dysregulation (Griffin, 2006).   In addition, activated astrocytes and microglia are 
found surrounding Aβ plaques in the brain, and the Aβ peptide functions as an activation 
signal for astrocytes (Combs, 2009) (Heneka, et al., 2010; Verkhratsky, et al., 2010).  
Furthermore, this activation of microglia and astrocytes is initially beneficial, but 
chronic activation and recruitment of microglia and astrocytes contribute to pathology 
and disease progression (Heneka, et al., 2010; Lee, et al., 2010; Wyss-Coray and Mucke, 
2002).     
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Another early event in the pathology of AD is amyloid plaque deposition.  
Amyloid plaques are comprised of Aβ peptides, which are a natural metabolic product of 
Amyloid Precursor Protein (APP), typically 36-43 amino acids in length (Querfurth and 
LaFerla, 2010).  The toxic form, Aβ42, is formed by the sequential cleavage of APP by 
beta-site amyloid precursor protein-cleaving enzyme 1 (β-secretase), encoded by 
BACE1, and γ-secretase, a protein complex involving the protein products of PSEN1 
and/or PSEN2 (Bekris, et al., 2010; Querfurth and LaFerla, 2010; Zhang, et al., 2011).  
Aβ begins as a monomer, but spontaneously aggregates to form oligomers (2-6 
peptides), which coalesce to form intermediate assemblies and eventually insoluble 
fibrils in a β-sheet formation that comprise the extracellular Aβ plaques (Iwatsubo, et al., 
1994; Jarrett, et al., 1993; Querfurth and LaFerla, 2010).  Not only does Aβ form 
insoluble plaques, but soluble dimers and trimmers have also been reported to be toxic to 
neuronal synapse (Querfurth and LaFerla, 2010).  Collectively, all of these disease 
pathways lead to cognitive decline and ultimately dementia.  One possible avenue of 
treatment is to prevent the transduction of destabilized Ca2+ homeostasis in to pathology, 
and this is possible through the inhibition of the S100 family of Ca2+ signaling proteins.   
The goal of this project is to ascertain the potential of S100A1/S100B inhibition 
as a treatment for AD and to identify an intracellular mechanism of S100A1/S100B 
function to aid in the development of drug targets for AD therapy.  The central 
hypothesis is that inhibition of intra- and extra-cellular S100A1/S100B will decrease 
plaque load and inflammation as well as normalize miRNA expression.  The specific  
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objectives for this study are: 
1) Quantify the effects of S100A1/S100B ablation on AD histopathology 
2) Determine the efficacy of S100A1/S100B immunotherapy on AD 
pathology 
3) Identify miRNA’s that contribute to S100A1/S100B mediated reversal of 
AD pathobiology.       
 
Figure 5.  The double transgenic PSAPP mouse model for AD. Depicted on the left is the process of crossing 
two single transgenic mouse lines (the ‘swedish’ APP mutation with a PS1 mutation) to generate the double 
transgenic PSAPP model.  On the right, parasagittal sections from the brain of PSAPP mice stained for Aβ at 6 
months (A), 12 months (B), 15 months (C), and 18 months (D) of age to illustrate the rapid development of 
plaques in the double transgenic PSAPP mouse.  (Gordon, et al., 2002).
TG2576
Tg(PrP-APPK670N,M671L)
PS1  5.1
Tg(PDGFB-PS1M146L)
PSAPP 
X
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Because there are no S100 specific inhibitors, this study uses two approaches to 
ascertain the net effect of S100A1 and S100B on in vivo AD histopathology, genetic 
ablation and passive immunotherapy.  We will use genetic ablation to recapitulate the 
entire spectrum of S100A1 and/or S100B function (detrimental and beneficial) in an AD 
mouse line.  The overt phenotypes of S100A1 and S100B knockout mice are normal and 
the only cellular phenotypes reported are modulatory changes in Ca2+ homeostasis 
(Prosser, et al., 2008; Xiong, et al., 2000).  We will also use passive immunotherapy to 
inhibit S100A1/S100B in the mouse model to ascertain the ability of S100 antibodies to 
mimic the genetic effects since passive immunotherapy is a viable treatment option for 
patients.  There are several different mouse models available to study AD but all express 
mutations that are found in the human early-onset form of AD.  Transgenic mouse  
models have had difficulty in reproducing the entire spectrum of AD pathologies, 
especially neuronal cell loss (Elder, et al., 2010).  Nonetheless mouse models have been 
instrumental in deciphering the molecular mechanisms of AD pathology and developing 
new therapies (Elder, et al., 2010; Gotz and Ittner, 2008; Morrissette, et al., 2009; Radde, 
et al., 2008).  The PSAPP double transgenic mouse used in this study expresses the 
“Swedish” APP mutation (APPK670N/M671L) and a PSEN1 mutation (PS-1M146L) (Figure 5) 
(Gordon, et al., 2001; Gordon, et al., 2002; Holcomb, et al., 1998; Holcomb, et al., 
1999).  Because this line has two overexpressing transgenes, the model has a rapid 
disease onset and mimics many facets of the human disease including plaque deposition, 
dystrophic neurites, glial activation, and memory deficits (Gordon, et al., 2001; Gordon, 
et al., 2002; Holcomb, et al., 1998; Holcomb, et al., 1999; Holcomb, et al., 2006).  In 
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order to generate the mice for this study, the PSAPP model was crossed to three different 
knockout lines, S100A1-/- to determine if S100A1 has an effect on AD pathology, 
S100B-/- in order to address the controversy in the field as to whether or not S100B has a 
role in AD pathology and S100A1-/-/S100B-/- to ascertain any synergistic effects of 
S100A1 and S100B (Figure 6).   
 
Figure 6.  Development of the PSAPP/S100 knockout mouse models. Depicted above is the strategy for 
developing the PSAPP/S100 genetic models utilized in these studies.  Double transgenic PSAPP mice will be 
crossed with each of the following lines to produce the PSAPP/S100 knockout lines: S100A1-/-, S100B-/- and     
S100A1-/-/S100B-/- (Prosser, et al., 2008; Roltsch, et al., 2010)
PSAPP/S100A1-/-
X
S100A1-/-
X
S100B-/- S100A1-/-/B-/-
X
PSAPP/S100B-/-
PSAPP
PSAPP/S100A1-/-/S100B-/-
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CHAPTER II 
PSAPP MICE EXHIBIT REGIONALLY SELECTIVE DECREASES IN GLIOSIS 
AND PLAQUE DEPOSITION IN RESPONSE TO S100B ABLATION* 
 
Background 
S100B, a member of the S100 protein family, is expressed predominantly in 
astrocytes and functions as both an intracellular Ca2+ receptor and an extracellular 
neuropeptide (Mrak and Griffin, 2004; Van Eldik and Wainwright, 2003; Zimmer, et al., 
2005). The term S100 to refers to the solubility of these 10,000 molecular weight 
proteins in saturated ammonium sulfate (Moore, 1965). S100 proteins are distinguished 
from other members of the S100/calmodulin/ troponin superfamily of EF-hand Ca2+ 
binding proteins by their 3 D structure and highly conserved 14 amino acid Ca2+ binding 
loop (Zimmer, et al., 2003). Upon binding Ca2+, S100 proteins undergo a conformational 
change which exposes a hydrophobic patch necessary for interacting with numerous 
intra- and extracellular protein targets and subsequent exertion of their biological effects 
(Zimmer, et al., 2003; Zimmer and Weber, 2010).  Over 20 intracellular targets have 
been reported for S100B suggesting that it regulates a large number of diverse cellular 
processes, including energy metabolism, cell proliferation, cytoskeleton organization, 
Ca2+ homeostasis and signal transduction pathways.  The extracellular effects of S100B  
____________ 
*Reprinted with permission from: Roltsch E, Holcomb L, Young KA, Marks A, Zimmer 
DB. PSAPP mice exhibit regionally selective reductions in gliosis and plaque deposition 
in response to S100B ablation. J Neuroinflammation 7:78 (2010) Copyright 2010 by 
BioMed Central Ltd. 
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are concentration dependent; nanomolar S100B levels beneficially promote neuronal 
survival while micromolar levels detrimentally promote apoptosis (Hofmann, et al., 
1999; Hu, et al., 1996; Leclerc, et al., 2010). S100B’s extracellular effects are thought to 
be mediated by the receptor for advanced glycation end products (RAGE) (Hofmann, et 
al., 1999; Leclerc, et al., 2010). S100B release/secretion is regulated by forskolin, 
lysophosphatidic acid, serotonin, glutamate, IL-6b, metabolites and the neurotoxic Aβ 
peptide (Pena, et al., 1995; Pinto, et al., 2000; Quincozes-Santos, et al., 2010; 
Tramontina, et al., 2006; Whitaker-Azmitia, et al., 1990) as well as being gender- and 
age-dependent (Nogueira, et al., 2009). Increased S100B levels are associated with a 
variety of neurological disorders including Alzheimer’s disease (AD), multiple sclerosis, 
amyotrophic lateral sclerosis, schizophrenia, epilepsy, alcoholism, drug abuse, hypoxia 
and traumatic brain injury (Mori, et al., 2010; Mrak and Griffin, 2004; Sorci, et al., 
2010; Van Eldik and Wainwright, 2003; Zimmer, et al., 2005).   
Altered S100B function is associated with AD pathobiology.  The clinical 
presentation and pathology of early- and late-onset AD include early disturbances in 
Ca2+ homeostasis followed by inflammation, neurodegeneration, senile plaques 
comprised of aggregated amyloid β (Aβ) peptide, intracellular neurofibrillary tangles 
comprised of aggregated hyperphosphorylated tau, and ultimately cognitive dysfunction 
(Demuro, et al., 2010; Querfurth and LaFerla, 2010; Small and Duff, 2008; Supnet and 
Bezprozvanny, 2010).  In human autopsy specimens, the highest levels of S100B 
expression are observed in the most severely affected regions and S100B associates with 
plaques (Marshak, et al., 1992; Van Eldik and Griffin, 1994; Van Eldik and Wainwright, 
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2003). Serum/CSF S100B levels inversely correlate with cognitive function, i.e. patients 
with lower S100B levels exhibit lower Clinical Dementia Rating scores and higher Mini-
Mental State Examination scores (Chaves, et al., 2010).  In addition, the rs2300403 
single nucleotide polymorphism (SNP) in the S100B gene is associated with low 
cognitive performance, dementia and AD (Lambert, et al., 2007).  While the cellular 
events/molecular mechanisms whereby S100B contributes to AD pathobiology have not 
yet been elucidated, S100B has been reported to regulate Aβ biogenesis, amyloid 
precursor protein expression/processing and tau hyperphosphorylation (Anderson, et al., 
2009; Esposito, et al., 2008; Mori, et al., 2010).  In turn, the Aβ peptide increases S100B 
levels (Chow, et al., 2010) resulting in a positive feedback loop.  Thus, S100B may be a 
key contributor to a detrimental “cytokine cycle” that drives the progression of AD 
(Leclerc, et al., 2010; Mrak and Griffin, 2004; Querfurth and LaFerla, 2010; Sen and 
Belli, 2007; Small and Duff, 2008; Sorci, et al., 2010; Van Eldik and Wainwright, 2003; 
Zimmer and Weber, 2010).   
In vivo studies in genetically modified mouse models have yielded conflicting 
results regarding the contribution of increased S100B expression to AD pathology.  
Transgenic TghuS100B mice express 4-5 fold more S100B protein (Friend, et al., 1992) 
and exhibit increased hippocampal gliosis with no change in plaque load upon 
hippocampal Aβ infusion when compared to non-transgenic controls (Craft, et al., 2005). 
However, TghuS100B/Tg2576 mice exhibit increased plaque load/gliosis in the 
hippocampus as well as the cortex when compared to Tg2576 mice (Mori, et al., 2010). 
The mechanism(s) responsible for the differential effects of increased S100B expression 
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on hippocampal pathology in the two AD models have not been elucidated. 
Pharmacological inhibition and genetic ablation have also produced contradictory 
results. Treatment of Tg2576 mice with arundic acid, an inhibitor of S100B expression 
(40-45% decrease), reduces plaque load/gliosis in the hippocampus and cortex (Mori, et 
al., 2006). Surprisingly, S100B ablation has no effect on hippocampal plaque load, 
gliosis or dystrophic neurons in an Aβ infusion model (Craft, et al., 2005).  Thus, the 
ability of S100B inhibitors to prevent/reverse AD histopathology is not completely 
understood.   
While specific inhibitors that block the interaction of S100B with its target 
proteins are under development, currently available compounds do not cross the blood 
brain barrier and cannot be used to inhibit CNS S100B (Markowitz, et al., 2007). 
Therefore, this study uses an in vivo genetic approach which recapitulates the entire 
spectrum of S100 function (detrimental, beneficial, intracellular, and extracellular) to 
ascertain the net effect of S100B ablation on AD histopathology in the PSAPP AD 
mouse line.  Although no AD mouse model exhibits all aspects of the human disease, the 
PSAPP double transgenic (APPK670NM671L/PS-1M146L) line has a rapid disease onset and 
mimics many facets of the human disease including plaque deposition, dystrophic 
neurites, glial activation, and memory deficits (Gordon, et al., 2001; Gordon, et al., 
2002; Holcomb, et al., 1998; Holcomb, et al., 1999). PSAPP/S100B knockout mice 
exhibited a regionally selective decrease in cortical but not hippocampal plaque load. 
Reductions in plaque load were accompanied by decreases in plaque number, GFAP-
positive astrocytes, Iba1-positive microglia and phospho-tau positive neurons. Finally, 
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S100B immunoreactivity in cortex and hippocampus of PSAPP mice was plaque 
associated and co-localized with astrocytes/microglia.  These results suggest that 
secreted and intracellular forms of S100B contribute to AD pathology and that 
pharmacological strategies which selectively block S100B action in the CNS may be 
effective in treating AD. 
Methods 
PSAPP X S100B knockout mice.  The PSAPP double transgenic line was generated by 
crossing the Tg2576 line ("Swedish” APPK670N/M671L mutation) with the 6.2 line (PS-
1M146L) (Gordon, et al., 2001; Gordon, et al., 2002; Holcomb, et al., 1998; Holcomb, et 
al., 1999). The S100B-/- line has been described previously (Xiong, et al., 2000). The 
PSAPP/S100B-/- line was generated by crossing PSAPP double transgenic males with 
S100B-/- females and subsequent interbreeding of the PSAPP/S100B+/- heterozygous 
offspring (PSAPP/S100B+/- X PSAPP/S100B+/-). To control for changes in genetic 
background, all experiments used PSAPP/S100B+/+ and PSAPP/S100B-/- littermates.  
Procedures involving animals were approved by the Texas A&M University Institutional 
Animal Care and Use Committee and comply with the NIH Guide for the Care and Use 
of Laboratory Animals.   
For genotyping, amplification of a 500 bp product using PCR primers for the 
mouse β-casein gene (forward primer 5’ GAT GTG CTC AG GCT AAA GTT 3’ and 
reverse primer 5’ AGA AAC GGA ATG TTG TGG AGT 3’) was used to assess 
genomic DNA quality.  The PS-1 and APP transgenes were detected as previously 
described [36]. Amplification of 250 bp band (forward primer 5’ GCA AAG AAC AGG 
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GTA GAA AAC ATG AAA AAC G 3’; reverse primer 5’ GCC ATT CAA ACT AAT 
ATC CAG AAG CAA CCC 3’) was used to detect the wild-type S100B allele. PCR 
programs contained a 5 minute denaturation step at 95°C; followed by thirty cycles 
consisting 1 minute at 94°C, 2 minutes at 60°C, and 3 minutes at 72°C; as well as a final 
7 minute extension step at 72°C. 
Sample acquisition/processing.  Brains were removed from anesthetized animals, 
rinsed in phosphate buffered saline (PBS) and fixed in 4% (wt/vol) paraformaldehyde in 
PBS for 30 minutes. Sagittal slices, 2 mm in thickness, were prepared using an acrylic 
brain matrix (Ted Pella, Redding CA) and post-fixed for an additional 30 minutes. Slices 
were then permeabilized in 2 mM MgCl2, 0.01% (wt/vol) sodium deoxycholate, 0.02% 
(vol/vol) Nonidet P-40 in 100 mM sodium phosphate buffer pH 7.5 for 36-48 hours.  
After post-fixation in 10% buffered formalin for 16 hours, tissues were embedded in 
paraffin and 5 micron sagittal sections were mounted on glass slides for subsequent 
staining.  This processing procedure, originally developed for visualization of β-
galactosidase reporter gene activity in transgenic mouse tissues, provides optimum 
S100B antibody specificity/sensitivity without compromising the detection of other 
antigens.  
Immunohistochemical and Congo red staining.  To minimize variability, sections 
from experimental and control groups were processed simultaneously. Consecutive 
slides (2/animal) each containing sections at Allen Brain Atlas Sagittal Levels 8 and 17 
were depariffinized and rehydrated to distilled water. For Congo red staining, slides 
were incubated in 0.02 M NaOH in 80% ethanol saturated with NaCl for 20 minutes 
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followed by a 30 minute incubation in 0.2% (wt/vol) Congo Red (Cat. 150711, MP 
Biomedicals, LLC, Solon, OH) in 0.02 M NaOH in 80% ethanol saturated with NaCl, 
dehydration and mounting. Immunostaining was performed on a DAKO autostainer 
(Dako, Carpentaria, CA) using a biotin-free polymer detection kit (MACH 2, Biocare 
Medical, Walnut Creek, CA) and conditions recommended by the primary antibody 
manufacturer. Primary antibodies for immunohistochemistry included a mouse 
monoclonal S100B antibody (1-1000 dilution of Z0311 Dako); rabbit polyclonal GFAP 
antibody (1-1000 dilution of Z0334, Dako); mouse monoclonal Iba1antibody (1-300 
dilution of SC-32725, Santa Cruz Biotechnology, Santa Cruz, CA); and mouse 
monoclonal Ser202/Thr205 phosphorylated tau antibody (1-20 dilution of MN1020, 
Pierce Chemical Co., Rockford, IL). For immunofluorescence microscopy, the anti-Iba1 
antibody was diluted 1-10, the anti-GFAP antibody 1-100, and the anti-S100B antibody 
1-50 (612377 from BD Transduction Laboratories, San Jose, CA). Secondary antibodies 
included an Alexa Fluor 546 donkey anti-rabbit (1-200 dilution of A10040, Molecular 
Probes, Carlsbad, CA); Alexa Fluor 488 rabbit anti-mouse (1-200 dilution of A11059, 
Molecular Probes); and Alexa Fluor 546 donkey anti-mouse (1-200 dilution of A10036, 
Molecular Probes).   
For quantification, digital images were captured at 10× magnification on an 
Olympus IX70 Imaging System using a single exposure setting as follows: the entire 
hippocampus (2 images); the visual (1 image), somatosensory (1 image) and 
somatomotor (1 image) cortex as well as representative areas of the cerebellum and 
olfactory bulb. Images were converted to gray scale and the threshold intensity was set 
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to the intensity observed in areas without tissue. Image J software (NIH Image, 
Bethesda, MD) was used to quantify positive pixels, plaque size, plaque number and 
total area. Plaque load and immunoreactivity were defined as the % area, i.e. the area of 
positive pixels/total pixels × 100. The data were expressed as the mean ± SEM (n= 8 for 
PSAPP and n= 6 for PSAPP/S100B-/-). An independent samples t-test (SPSS Inc., 
Chicago, IL) was used to determine the significance (p < 0.05) of measured differences 
between the two genotypes. Pearson’s Correlation Coefficient and scatter plots of the 
mean hippocampal and cortical GFAP/Iba1 staining versus plaque load for each animal 
were used to determine the relationship between plaque load and 
astrocytosis/microgliosis.  
Images for colocalization experiments were obtained on a Zeiss 510 META NLO 
laser scanning microscope.  The following settings were used for fluorophore detection: 
DAPI excitation G 365, Dichroic FT 395, BP 445/50; for Alexa 488, exciter BP 470/20, 
Dichroic FT 493, Emission BP 505-530; and Alexa 568, Exciter BP 560/40, Dichroic FT 
585, Emission BP 630/75. Images were collected, corrected for background and bleed 
through (reference images) and colocalization (overlap coefficient) of GFAP/S100B and 
Iba1/S100B determined using the LSM software. 
Results 
S100B ablation reduces cortical but not hippocampal plaque load.  To determine if 
S100B ablation altered amyloidogenesis, plaque load was quantified in PSAPP/S100B 
knockout and PSAPP mice.  Congo red stained fibrillar plaques were observed in the 
hippocampus and cortex of 6 month old PSAPP/S100B-/- and PSAPP mice (Figure 7A).    
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Figure 7:  S100B ablation reduces cortical, but not hippocampal plaque load.  Panel A contains 
representative micrographs of parasagittal cortical/hippocampal sections from 6 month old PSAPP and  
PSAPP/S100B-/- mice stained with congo red (pink) and hematoxylin (blue) to visualize plaques and 
nuclei, respectively.  The histograms depict the mean congophilic plaque load (Panel B), plaque number 
(Panel C), and plaque size (Panel D) + SEM in PSAPP (black bars, n=8), and PSAPP/S100B-/- (red bars, 
n=6) mice.  Scale bars represent 50 microns and asterisks denote p0.05 when compared to the PSAPP 
group.
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In fact, congophilic plaque load in the control PSAPP littermates was indistinguishable 
from previous reports (Gordon, et al., 2001; Gordon, et al., 2002; Holcomb, et al., 1998).  
Furthermore, hippocampal plaque load in the two genotypes was indistinguishable: 
0.070 ± 0.020 and 0.075 ± 0.022 percent area in the PSAPP/S100B-/- and PSAPP 
controls, respectively (Figure 7B). Hippocampal plaque size and number were also 
similar in the two genotypes (Figure 7C and 7D). In contrast, there was a 3-fold 
reduction in cortical plaque load in PSAPP/S100B-/- mice (0.050 ± 0.016 percent area) 
when compared to PSAPP mice (0.168 ± 0.016 percent area) (Figure 7B). This decrease 
in cortical plaque load was accompanied by an 5-fold reduction in plaque number (47.78 
± 9.42 vs. 8.78 ± 2.07) and a slight increase in plaque size (1162 ± 141 vs. 1955 ± 196 
μm2) (Figure 7C and 7D).  In summary, this is the first demonstration that S100B 
ablation selectively reduces cortical plaque load. 
S100B ablation reduces cortical, but not hippocampal, gliosis.  S100B’s deleterious 
effects in the central nervous system have been attributed to reactive gliosis (astrocytosis 
and microgliosis) (Craft, et al., 2005; Mori, et al., 2006; Mori, et al., 2010; Van Eldik 
and Griffin, 1994). The microglial marker Iba1 and astrocytic marker GFAP were used 
to determine if S100B ablation in PSAPP mice also reduced gliosis.  Plaque-associated 
Iba1 staining of small cell bodies and long processes was observed in the cortex and 
hippocampus of PSAPP and PSAPP/S100B-/- mice (Figure 8A and 8B). This staining 
pattern was similar to previous reports for AD mouse models (Tg2576) (Mori, et al., 
2006; Mori, et al., 2010). Hippocampal Iba1 staining in the two genotypes was similar 
(0.51 ± 0.12 vs. 0.51 ± 0.10 percent area) (Figure 8C).  However, cortical Iba1 staining  
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Figure 8: S100B ablation reduces cortical microgliosis. Representative photomicrographs of parasagittal 
cortical/hippocampal sections from 6 month old PSAPP and PSAPP/S100B-/- mice are shown stained with an Iba1 
antibody which labels microglia (Panel A) and co-stained with Iba1 and congo red, which labels fibrillar plaques, 
to demonstrate plaque associated microglial staining (Panel B).  The histograms in Panel C depict the mean Iba1 
positive area + SEM in PSAPP (black bars, n=8), and PSAPP/S100B-/- (red bars, n=6), mice.  Scale bars represent 
50 microns and asterisks denote p0.05 when compared to the PSAPP group.  Panel D is a scatter plot of the mean 
Iba1 burden versus plaque load for each animal (cortex and hippocampus).   
 
was 4-fold less (0.45 ± 0.09 vs. 1.69 ± 0.49 percent area) in PSAPP/S100B-/- mice when 
compared to PSAPP control mice (Figure 8C). In both genotypes, the Iba1 staining was 
similar in non-plaque containing regions such as the cerebellum (Figure 8A) and 
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olfactory bulb (data not shown).  Furthermore, there was a direct correlation between 
Iba1 staining and plaque load (Pearson’s Correlation Coefficient 0.654, p < 0.0005)  
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Figure 9: S100B ablation reduces cortical astrocytosis.  Representative photomicrographs of parasagittal 
cortical/hippocampal sections from 6 month old PSAPP and PSAPP/S100B-/- mice shown stained with a GFAP 
antibody which recognizes activated astrocytes (Panel A) and co-stained with GFAP and congo red which 
recognizes fibrillar plaques to demonstrate plaque associated astrocytic staining (Panel B).  The histogram in Panel 
C illustrates the mean GFAP positive area + SEM in PSAPP (black bars, n=8), and PSAPP/S100B-/- (red bars, n=6) 
mice.  Scale bars represent 50 microns and asterisks denote p0.05 when compared to the PSAPP group. Panel D is 
a scatter plot of the mean GFAP burden versus plaque load for each animal (cortex and hippocampus). 
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(Figure 8D). Hippocampal/ cortical plaque-associated GFAP positive astrocytes were 
also observed in both genotypes (Figure 9A and 9B) and the staining pattern (somata and 
processes) was indistinguishable from previous reports for AD mouse models (Mori, et 
al., 2006; Mori, et al., 2010). Hippocampal GFAP staining was similar (4.53 ± 0.67 vs. 
5.52 ± 1.35 percent area) while cortical GFAP staining was 2-fold less (3.56 ± 0.92 vs. 
7.26 ± 1.40 percent area) in PSAPP/S100B-/- mice when compared to PSAPP control 
mice (Figure 9C). In addition, GFAP staining in non-plaque containing regions such as 
the cerebellum (Figure 9A) and olfactory bulb (data not shown) was similar in the two 
genotypes. Like Iba1, there was a direct correlation between GFAP staining and plaque 
load (Pearson’s Correlation Coefficient 0.722 p < 0.0005) (Figure 9D). Collectively, 
these findings demonstrate that S100B ablation results in regionally selective decreases 
in microgliosis and astrocytosis that directly correlate with plaque load. 
Effects of S100B ablation on dystrophic neurons.  Although the correlation between 
plaque load and cognitive function remains controversial, decreases in plaque load are 
commonly accompanied by reductions in dystrophic neurons/neurites and improvements 
in cognitive function. In fact, changes in phospho-tau levels/ staining are used to detect 
dystrophic neurons in PSAPP and Tg2576 mice despite the fact that these models do not 
develop tangles (Giunta, et al., 2009; Ricobaraza, et al., 2009; Tomiyama, et al., 2010). 
Therefore, the AT8 phospho-tau antibody, which detects phospho-Ser202/Thr205, was 
used to ascertain the effect of S100B ablation on dystrophic neurons. The hippocampal 
and cortical phospho-tau staining patterns in both genotypes was indistinguishable from 
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previous reports: punctate plaque-associated staining (Figure 10).  These results 
demonstrate that S100B ablation does not prevent the development of plaque-associated  
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Figure 10: S100B ablation reduces cortical phospho-tau staining.  Representative photomicrographs of 
parasagittal cortical and hippocampal sections from 6 month old PSAPP and PSAPP/S100B-/- mice co-stained with 
the AT8 antibody which recognizes tau phosphorylated at Ser202/Thr205 and congo red to visualize plaque 
associated dystrophic neurites.  Scale bars represent 50 microns. 
 
 
dystrophic neurons.  However, as predicted by the plaque load results, PSAPP/S100B-/- 
mice exhibited fewer cortical but similar numbers of hippocampal phospho-tau 
foci/plaques when compared to PSAPP mice (Figure 10). 
S100B colocalizes with hippocampal as well as cortical astrocytes, microglia, and 
plaques.  In human autopsy specimens and the Tg2576 mouse model, S100B staining is 
associated with astrocytes and plaques (Marshak, et al., 1992; Mori, et al., 2010; Van 
 28
Eldik and Griffin, 1994). In addition, in human AD the highest levels of S100B are 
observed in the most severely affected regions (Van Eldik and Griffin, 1994). Therefore, 
S100B immunohistochemistry was used to determine if differences in S100B  
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Figure 11:  S100B distribution in PSAPP mice. Representative photomicrographs of parasagittal cortical and 
hippocampal sections from 6 month old PSAPP, non-transgenic littermates or S100B-/- mice co-stained with an 
S100B antibody and congo red. Insets provide higher magnification of representative plaques.  Scale bars represent 
50 microns.  
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distribution were responsible for the regionally selective effects of S100B ablation on 
histopathology in PSAPP mice. In nontransgenic mice, intense staining of astrocytic cell 
bodies/processes and diffuse cytoplasmic/extracellular S100B staining was observed in 
the hippocampus and cortex (Figure 11). PSAPP mice exhibited a similar staining 
pattern as well as punctate plaque-associated staining (Figure 11). The increased staining 
intensity in PSAPP mice when compared to nontransgenic mice is consistent with 
previous reports of increased S100B expression in AD (Mrak and Griffin, 2004; Van 
Eldik and Wainwright, 2003; Zimmer, et al., 2005). Sections from PSAPP/S100B-/- mice 
exhibited no detectable staining (Figure 11) indicating that plaque associated and diffuse 
cytoplasmic/extracellular staining were not attributable to non-specific antibody binding 
and/or high background.  The S100B staining pattern observed in PSAPP mice  
was similar to staining patterns observed in the Tg2576 AD mouse model (Mori, et al., 
2006) and human autopsy specimens (Sheng, et al., 1996). The cellular distribution of 
S100B in PSAPP mice was confirmed by double immunofluorescence staining with 
astrocytic (GFAP, overlap coefficient 0.8083 ± 0.0149) and microglial (Iba1, overlap 
coefficient 0.8476 ± 0.0356) markers (Figure 12).  Collectively, these findings suggest 
that both intracellular and extracellular forms of S100B may contribute to AD 
histopathology. In conclusion, the regionally selective effects of S100B ablation on 
histopathology are most likely attributable to regional differences in the cellular  
processes that are regulated by S100B and not differences in S100B 
expression/distribution.  
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S100BGFAP Iba1S100B
Figure 12:  S100B staining co-localizes with plaques, microglia and astrocytes.   Representative fluorescent 
micrographs of parasagittal cortical sections from 6 month old PSAPP mice co-stained with a GFAP (red) and an 
S100B (green) antibody or an Iba1 (green) and an S100B (red) antibody. Yellow denotes co-localization of S100B 
with astrocytes and microglia.  Scale bars represent 50 microns.  
 
 
Discussion 
This study definitively demonstrates that S100B ablation/inhibition reduces AD 
pathology. PSAPP/S100B knockout mice exhibited a regionally selective decrease in 
cortical but not hippocampal plaque load that was accompanied by reductions in 
astrocytosis, microgliosis and dystrophic neurons. These regionally selective effects 
were not attributable to variations in the S100B distribution; cortical and hippocampal 
S100B staining patterns were indistinguishable in PSAPP mice. Finally, in PSAPP mice 
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S100B immunoreactivity was associated with plaques and colocalized with astrocytes as 
well as microglia suggesting that both intracellular and extracellular S100B contribute to 
AD histopathology.  Interestingly, other studies have reported regionally selectively 
effects of S100B ablation on Ca2+ handling, synaptic plasticity, kainate-induced gamma 
amplitudes and BDNF (brain-derived neurotrophic factor) levels (Nishiyama, et al., 
2002; Sakatani, et al., 2007; Sakatani, et al., 2008; Schulte-Herbruggen, et al., 2008). 
Ascertaining the molecular mechanisms responsible for S100B’s selective effects on AD 
histopathology and other processes may provide new insights into the events that 
contribute to the non-uniform progression of AD (Gomez-Isla, et al., 1996; Hyman, et 
al., 1984; Romito-DiGiacomo, et al., 2007).   
These findings clarify inconsistencies in the literature regarding S100B’s 
contribution to AD histopathology.  Genetic ablation (this study), pharmacological 
inhibition (Mori, et al., 2006) and genetic overexpression (Mori, et al., 2010) approaches 
consistently indicate that decreases in S100B reduce AD histopathology in the cortex. 
The larger effects observed with genetic ablation may be due to maximal inhibition; 
pharmacological inhibition reduces S100B levels by 40-50% and genetic overexpression 
increases S100B levels by 30% (Mori, et al., 2006; Mori, et al., 2010). In all S100B-/- 
mice, hippocampal plaque load remains unchanged regardless of the mechanism used to 
induce plaque deposition, i.e. Aβ infusion (Craft, et al., 2005) or overexpression of 
mutant proteins (APP and PS-1) in transgenic mice (this study). However, 
pharmacological inhibition of S100B synthesis with arundic acid in mice that 
overexpress mutant APP (TG2576 line) reduces hippocampal plaque load/gliosis (Mori, 
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et al., 2006) and overexpression of S100B in the same model increases hippocampal 
plaque load/gliosis (Mori, et al., 2010). These differential effects may be due to 
alternative mechanisms of action for arundic acid (Asano, et al., 2005), upregulation of 
compensatory mechanisms in knockout models, gain of function in overexpression 
models, differences in the AD mouse models and/or variations the ages of the animals.  
A consistent finding in this and previous studies is a direct correlation between 
changes in plaque load and gliosis/inflammation in response to alterations in S100B 
expression. It is unclear, however, whether changes in plaque load are the cause or the 
result of changes in gliosis. Furthermore, it is unclear how these histopathological 
changes impact cognitive function. Microglia are an essential component of the 
inflammatory response and exist in many forms (Morgan, 2006; Perry, et al., 2010). 
They beneficially phagocytize plaques and suppress inflammation as well as 
detrimentally promote inflammation and neuronal cell death (Fuhrmann, et al., 2010; 
Heneka, et al., 2010; Lee and Landreth, 2010). Detailed analyses of microglial/glial 
phenotypes in   PSAPP/S100B-/- mice will be instrumental in identifying S100B-
regulated events that contribute to AD pathology and in discerning the relationship 
between plaques and inflammation. Behavioral data are not available for any of the 
S100B/AD mouse models.  Strengthened synaptic plasticity and enhanced spatial 
memory in S100B-/- mice (Nishiyama, et al., 2002) suggest that PSAPP/ S100B-/- mice 
will exhibit improved cognitive function.  This hypothesis is supported by the inverse 
correlation of serum/CSF S100B levels and the direct correlation of the rs2300403 SNP 
in the S100B gene with low cognitive performance, dementia and AD (Chaves, et al., 
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2010; Lambert, et al., 2007). Experiments are underway to determine if pharmacological 
inhibition of S100B expression and/or interaction of S100B with its target proteins will 
improve cognitive function in AD and/or other neurological disorders.   
S100B’s plaque association and co-localization with cells (microglia/astrocytes) 
in this and previous studies (Marshak, et al., 1992; Mori, et al., 2006; Van Eldik and 
Griffin, 1994) suggest that both intracellular and extracellular S100B contribute to AD 
pathology.  Inhibition of intracellular S100B would be predicted to reduce Aβ induced 
spontaneous calcium transients (Chow, et al., 2010), decrease inflammatory cytokine 
release (Mrak and Griffin, 2004; Sen and Belli, 2007; Van Eldik and Wainwright, 2003) 
and prevent Aβ induced increases in S100B levels (Pena, et al., 1995). Inhibition of 
extracellular S100B would be predicted to alter Ca2+ handling, synaptic plasticity long-
term potentiation, neuronal apoptosis and/or BDNF levels (Fulle, et al., 2000; 
Nishiyama, et al., 2002; Rebaudo, et al., 2000; Sakatani, et al., 2007; Sakatani, et al., 
2008; Schulte-Herbruggen, et al., 2008; Sheng, et al., 1996; Xiong, et al., 2000).  
Decreased extracellular S100B-RAGE/scavenger receptor signaling in glia, neurons 
and/or endothelial cells (Deane and Zlokovic, 2007; Hofmann, et al., 1999; Hoppmann, 
et al., 2010; Hu, et al., 1996; Perrone, et al., 2008; Takeuchi and Yamagishi, 2008; Yan, 
et al., 1996; Yan, et al., 2009) could also impact APP synthesis, APP processing and/or 
tau phosphorylation (GSK3β, cdk5 and/or PKA pathways) (Demuro, et al., 2010; 
Querfurth and LaFerla, 2010; Small and Duff, 2008; Supnet and Bezprozvanny, 2010). 
In fact, intracellular/extracellular S100B may link dysregulation of Ca2+ homeostasis 
with AD pathobiology and/or serve as a common upstream regulator of both tau 
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phosphorylation/neurofibrillary tangles and Aβ production/plaque deposition (Demuro, 
et al., 2010; Querfurth and LaFerla, 2010; Small and Duff, 2008; Supnet and 
Bezprozvanny, 2010). While astrocytes, microglia and oligodendrocytes are the most 
logical source of S100B, peripheral tissues such as adipose cannot be excluded (Pham, et 
al., 2010; Steiner, et al., 2010; Steiner, et al., 2010). Defining the source of and 
mechanisms of release/secretion for S100B will be important steps in delineating the 
S100B-regulated processes that contribute to AD histopathology. 
Conclusions 
Collectively, these data definitively demonstrate that S100B ablation reduces 
plaque load, gliosis and dystrophic neurons in the cortex but not the hippocampus. If this 
reduction in histopathology can be demonstrated to positivity impact cognitive changes 
related to AD, then additional impetus to the search for new therapeutic interventions 
targeted at S100B will be provided. The development of effective pharmacological 
strategies for modulating S100B function in patients will also require quantifying the 
contribution of extracellular versus intracellular forms, identifying the S100B-regulated 
target proteins/cellular processes, and ascertaining the contribution of the five other 
S100 family members implicated in AD, S100A1, S100A6, S100A7, S100A9, and 
S100A12 (Boom, et al., 2004; Qin, et al., 2009; Shepherd, et al., 2006; Zimmer, et al., 
2005). Finally, the beneficial effects of S100B ablation/inhibition may extend to other 
neurological disorders that involve dysregulation of glial cell calcium homeostasis 
(Matute, 2010; Nedergaard, et al., 2010). 
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CHAPTER III 
S100A1 ABLATION REDUCES ALZHEIMER’S DISEASE PATHOLOGY IN THE 
PSAPP MOUSE MODEL  
 
Background 
S100A1 is a member of the S100 family of Ca2+ and Zn2+ binding proteins. The 
term S100 to refers to the solubility of these low molecular weight (~10,000 kDa) 
proteins in saturated ammonium sulfate (Moore, 1965).  S100 proteins are distinguished 
from other members of the S100/calmodulin/troponin superfamily of EF-hand Ca2+ 
binding proteins by their 3D structure and highly conserved 14 amino acid Ca2+ binding 
loop (Haass and Selkoe, 2007).  Upon binding Ca2+, S100 proteins undergo a 
conformational change which exposes a hydrophobic patch necessary for interacting 
with numerous intra- and extracellular protein targets and subsequent exertion of their 
biological effects (Haass and Selkoe, 2007).  Individual S100 family members regulate a 
large number of diverse target proteins/cellular processes that include energy 
metabolism, cell proliferation, cytoskeletal organization, Ca2+ homeostasis and signal 
transduction pathways.  The number/diversity of S100 target proteins, modulatory 
effects of S100s on target protein activity under physiological conditions and absence of 
overt phenotypes in knockout mice has led to the misconception that S100s are 
redundant and play a minor role in Ca2+ signaling. In reality, S100s are uniquely suited 
to transduce changes in a universal second messenger into spatially and temporally 
unique biological responses (Zimmer and Weber, 2010). The diversity among family 
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members coupled with their overlapping but distinct expression patterns and partial 
functional redundancy confers cell-type diversity/specificity to signaling.  Furthermore, 
their interaction with and regulation of multiple components within a given 
pathway/process allows for cross-talk between and feedback loops within pathways. 
Nonetheless, the most dramatic effects of S100 signaling are observed under non-
physiological conditions and often associated with increases in intracellular calcium 
levels.  For example, increased S100A1 levels delay the conversion of beneficial cardiac 
hypertrophy to detrimental cardiomyopathy (Most, et al., 2007).  In contrast, a 
detrimental gain of S100B function contributes to unregulated melanoma cell growth 
(Markowitz, et al., 2007).  
Six members of the S100 family have been implicated in the onset/progression of 
AD: S100A1, S100A6, S100A7, S100A9, S100A12 and S100B (Boom, et al., 2004; 
Chaves, et al., 2010; Qin, et al., 2009; Shepherd, et al., 2006; Steiner, et al., 2011; 
Zimmer, et al., 2005). S100B is hypothesized to contribute to a “detrimental cytokine 
cycle” that drives the progression of AD (Leclerc, et al., 2010; Mrak and Griffin, 2004; 
Querfurth and LaFerla, 2010; Sen and Belli, 2007; Small and Duff, 2008; Sorci, et al., 
2010; Van Eldik and Wainwright, 2003; Zimmer and Weber, 2010) and recent studies 
have identified inhibition of S100B as a novel strategy for reducing plaque load, gliosis 
and neuronal dysfunction (Roltsch, et al., 2010).  S100A9 and S100A12 are 
inflammation associated proteins, constitutively expressed in neutrophils and induced in 
plaque associated macrophages (Shepherd, et al., 2006). S100A6 is upregulated in 
astrocytes that surround plaques in human autopsy specimens and transgenic mice 
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(Boom, et al., 2004). S100A7, originally characterized as a marker for psoriasis (Ruse, et 
al., 2001), is present in the CSF of AD patients and promotes non-amyloidogenic APP 
processing (Qin, et al., 2009).  In the case of S100A1, there is no information regarding 
S100A1expression/function in the AD brain.  However, S100A1 does regulate numerous 
cellular processes/target proteins that have been implicated in AD. 
S100A1 is expressed primarily in neurons and functions as both an intracellular 
Ca2+ receptor and an extracellular neuropeptide (Wright, et al., 2009; Zimmer, et al., 
1998; Zimmer, et al., 2005).  S100A1 has been reported to regulate several cellular 
processes that are involved in AD including APP expression, tau phosphorylation, 
neuronal cell sensitivity to Aβ, dendrite/synapse formation, neuronal survival and Ca2+ 
homeostasis (Zimmer, et al., 1998; Zimmer, et al., 2005).  In addition, many S100A1-
target proteins exhibit altered function in AD including the ryanodine receptor, tau, 
RAGE-receptor and Akt (Bruno, et al., 2011; Castellani, et al., 2010; Huttunen, et al., 
2000; Leclerc, et al., 2009; Prosser, et al., 2011; Querfurth and LaFerla, 2010; Srikanth, 
et al., 2011; Wright, et al., 2009; Zimmer, et al., 2005).  However, we do not know if 
S100A1 is expressed in the AD brain and if so, is it beneficial or detrimental.  
This study uses an in vivo genetic approach to ascertain the net effect of S100A1 
ablation on AD histopathology in the PSAPP AD mouse line. Although no AD mouse 
model exhibits all aspects of the human disease, the PSAPP double transgenic 
(APPK670NM671L/PS-1M146L) line has a rapid disease onset and mimics many facets of the 
human disease including plaque deposition, dystrophic neurites, glial activation, and 
memory deficits (Gordon, et al., 2001; Gordon, et al., 2002; Holcomb, et al., 1998; 
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Holcomb, et al., 1999).  Immunohistochemistry confirmed that PSAPP and human 
autopsy specimens contain S100A1, some of which is plaque-associated. 
PSAPP/S100A1 knockout mice exhibited reductions in cortical and hippocampal plaque 
load that were attributable to decreases in plaque number, not plaque size. These 
reductions in plaque load were accompanied by decreased inflammation, i.e. GFAP-
positive astrocytes and Iba1-positive microglia.  Finally, ablation of both S100A1 and 
S100B had synergistic effects on plaque load in 6 but not 12 month old animals.  These 
results suggest that S100A1 and S100B act via different mechanisms in young animals 
and that their mechanisms of action in AD are dynamic/flexible.  In summary, this is the 
first report of in vivo synergy among S100 family members. These findings suggest that 
intracellular as well as extracellular forms of S100A1 contribute to AD pathology and 
that pharmacological strategies which selectively block S100A1 action in the CNS may 
be effective treatments for AD.   
Methods 
PSAPP X S100A1 knockout mice.  The PSAPP double transgenic line (Gordon, et al., 
2001; Gordon, et al., 2002; Holcomb, et al., 1998; Holcomb, et al., 1999) and S100A1 
knockout line (Prosser, et al., 2008) have been described previously.  The 
PSAPP/S100A1-/- and PSAPP S100 double knockout (PSAPP/S100A1-/-/S100B-/-) lines 
were generated by crossing PSAPP double transgenic males with S100A1-/-/S100B-/- 
knockout females and subsequent interbreeding of the heterozygous offspring 
(PSAPP/S100A1+/-/S100B+/- X PSAPP/S100A1+/-/S100B+/-).  To control for genetic 
background, all experiments used PSAPP/S100A1+/+/S100B+/+, PSAPP/S100A1-/-
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/S100B+/+, and PSAPP/S100A1-/-/S100B-/-littermates.  Genotyping was performed as 
previously described (Gordon, et al., 2001; Prosser, et al., 2008; Roltsch, et al., 2010).  
All procedures involving animals were approved by the Texas A&M University 
Institutional Animal Care and Use Committee and comply with the NIH Guide for the 
Care and Use of Laboratory Animals. 
Sample acquisition/processing.  Brains were removed from anesthetized animals and 
processed as previously described (Roltsch, et al., 2010).  Briefly, brains were rinsed in 
phosphate buffered saline (PBS), fixed in 4% (wt/vol) paraformaldehyde in PBS for 30 
minutes and sliced into 2 mm sagittal sections.  After a second 30 minute fixation in 4% 
(wt/vol) paraformaldehyde in PBS, slices were permeablized in 2mM MgCl2, 0.01% 
(wt/vol) sodium deoxycholate, 0.02% (vol/vol) Nonidet P-40 in 100mM sodium 
phosphate buffer pH 7.5 (permeabilization buffer), post-fixed in 10% buffered formalin 
for 16 hours and embedded in paraffin.  Five micron sagittal sections were mounted on 
glass slides for subsequent staining.  Alzheimer’s tissue arrays containing parietal cortex, 
temporal cortex, prefrontal cortex, and hippocampal specimens from age- and gender-
matched normal and AD patients (CERAD semi-quantitative assessment criteria 
confirmed) were obtained as a catalog item from Folio Biosciences (ARY-HH0116) 
(Columbus, OH).    
Immunohistochemical and Congo red staining.  Congo-red (plaque load), Iba1 
(microgliosis), GFAP (astrocytosis) and S100A1 staining were performed as previously 
described (Roltsch, et al., 2010).  Primary antibodies included a mouse monoclonal 
S100A1 antibody (1-300 dilution of SC-58840, Santa Cruz Biotechnology, Santa Cruz, 
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CA), a rabbit polyclonal GFAP antibody (1-1000 dilution of Z0311, Dako, Carpentaria, 
CA) and mouse monoclonal Iba1 antibody (1-300 dilution of SC32735, Santa Cruz 
Biotechnology).  For quantification, digital images were captured, converted to gray 
scale, and positive pixels, plaque size, plaque number and total plaque load were 
quantified using Image J software (NIH Image, Bethesda, MD).  Plaque load and 
immunoreactivity were defined as the % area, i.e. the area of positive pixels/total pixels 
X 100.  The data were expressed as the mean + SEM (n=8 for 6 and 12 month old 
PSAPP, n=8 for 6 month old PSAPP/S100A1-/- and n=3 for 12 month PSAPP/S100A1-/-, 
n=6 for 6 month old PSAPP/S100A1-/-/S100B-/- and n=4 for 12 month old 
PSAPP/S100A1-/-/S100B-/-).  A multicomparison ANOVA with the Tukey HSD post hoc 
test or an independent samples t-test (JMP by SAS, Cary, NC) was used to determine the 
significance (p<0.05) of measured differences between genotypes.  The Orthogonal 
Regression Correlation and scatter plots of the mean hippocampal and cortical 
GFAP/Iba1 staining/animal versus plaque load were used to determine the relationship 
between plaque load and astrocytosis/microgliosis. 
Results 
Mouse and human AD brain specimens contain S100A1. Immunohistochemistry was 
used to determine if S100A1 is present in the AD brain. In PSAPP mice, S100A1 
staining was detectable in the cerebellum (Figure 13A), cortex and hippocampus (data 
not shown) at 6 and 12 months of age. In addition, the concentrated perinuclear as well 
as diffuse cytoplasmic/extracellular staining in the gray matter with little or no staining 
in the white matter pattern was similar to previous reports (Benfenati, et al., 2004; 
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Zimmer and Landar, 1995; Zimmer, et al., 1995).   However there was one notable 
exception, plaque-associated S100A1 staining. PSAPP/S100A1 knockout mice exhibited  
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Figure 13.  S100A1 distribution in PSAPP mice. Representative photomicrographs of parasagittal cerebellar 
(Panel A) and cortical (Panel B) sections from PSAPP (a and d), nontransgenic (b) and PSAPP/S100A1-/- (c and e) 
mice either stained with an S100A1 antibody (a, b and c) or co-stained with an S100A1 antibody and Congo red 
(d and e).        
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no detectable S100A1 staining (Figure 13) indicating that the cellular and plaque-
associated S100A1 staining was not attributable to non-specific antibody binding and/or 
high background.  Since no AD mouse model recapitulates all aspects of pathology 
observed in human patients (Elder, et al., 2010), age- and gender-matched 
control/CERAD AD confirmed human tissue arrays were used to determine if human 
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AD brains contained S100A1.  S100A1 staining was detected in the parietal cortex, 
temporal cortex, prefrontal cortex and hippocampus in AD and control specimens 
(Figure 14).  Furthermore, the staining pattern was similar to that observed in the mouse: 
concentrated perinuclear staining, diffuse/extracellular cytoplasmic staining and plaque-
associated staining in the gray matter.  Additional studies will be needed to determine if 
plaque associated staining in mouse models and human AD represents intracellular  
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Figure 14.  S100A1 distribution in human AD specimen.  Representative photomicrographs of human tissue 
arrays containing cortical and hippocampal sections from Alzheimer’s disease and age-matched controls 
stained with an S100A1 antibody (brown) and counterstained (Panel A).  Panel B depicts higher magnification 
of representative plaques in human cortical AD specimens stained with an S100A1 antibody (blue) and an 
Aβ1-40 antibody (brown) which labels plaques.   
 
S100A1 within dystrophic neurites/activated microglia or extracellular S100A1 within 
the plaque. Nonetheless, this is the first demonstration that mouse and human AD brain 
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specimens contain S100A1 and suggests that aberrant S100A1 signaling in response to 
Ca2+ dysregulation may contribute to AD pathobiology.    
S100A1 ablation decreases plaque load in PSAPP mice.  To determine if S100A1 
ablation altered amyloidogenesis, plaque load was quantified in PSAPP/S100A1 
knockout and PSAPP mice.  In 6 month old animals, Congo red positive plaques were 
observed in the hippocampus and cortex of both genotypes (Figure 15A).  However, 
PSAPP/S100A1-/- mice exhibited a 3.5 fold reduction in cortical plaque load (0.0481 ± 
0.0062 vs.  0.1676 ± 0.0156 percent area) and a 2.4 fold reduction in hippocampal 
plaque load (0.0351 ± 0.0800 vs. 0.0845 ±0.0220 percent area) when compared to 
PSAPP mice (Figure 15B).  This decrease in plaque load was attributable to a decrease 
in plaque number, not plaque size.  PSAPP/S100A1-/- exhibited a 3.6 fold reduction in 
cortical (13.3333 ± 1.4885 vs. 47.7778 ± 9.4204) and a 3 fold reduction in hippocampal 
(3.8889 ± 0.9562 vs. 11.2500 ± 3.8580) plaque number (Figure 15C).   In contrast, the 
plaque size in the two genotypes was indistinguishable: 1358 ± 104 vs. 1162 ± 141 μm2 
in the cortex and 1952 ± 421 vs. 1864 ± 711 μm2 in the hippocampus (Figure 15D).  
Plaque load in PSAPP littermates was indistinguishable from previously published 
reports (Gordon, et al., 2001; Gordon, et al., 2002; Holcomb, et al., 1998; Holcomb, et 
al., 1999; Roltsch, et al., 2010) indicating the these differences were not attributable to 
genetic background.  
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Figure 15:  S100A1 ablation reduces cortical and hippocampal plaque load in six month old PSAPP 
mice.  Panel A contains representative micrographs of parasagittal cortical/hippocampal sections from 6 
month old PSAPP and  PSAPP/S100A1-/- mice stained with congo red (pink) and hematoxylin (blue) to 
visualize plaques and nuclei, respectively.  The histograms depict the mean congophilic plaque load (Panel 
B), plaque number (Panel C), and plaque size (Panel D) + SEM in PSAPP (solid blue bars, n=8), and 
PSAPP/S100A1-/- (hatched blue bars, n=4) mice.  Asterisks denote p0.05 when compared to the PSAPP 
group.
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 To determine if the effects of S100A1 ablation on plaque load were age-
dependent, plaque load was quantified in 12 month old animals. As expected, 12 month 
old PSAPP littermates exhibited a 6-7 fold increase in plaque load when compared to 6 
month old PSAPP mice. Nonetheless, there was a 3 fold reduction in cortical (0.3212 ± 
0.0257 vs. 1.023 ± 0.0354 percent area) and a 2 fold reduction in hippocampal (0.2478 ± 
0.0414 vs. 0.5511 ± 0.0684 percent area) plaque load in 12 month old PSAPP/S100A1-/- 
mice (Figure 16A and B).  In addition, these reductions in plaque load were attributable 
to decreases in plaque number, not plaque size. PSAPP/S100A1-/- mice exhibited a 2 
fold reduction in cortical (83.0 ± 12.3 vs. 179.8 ± 10.9) and hippocampal (24.7 ± 5.5 vs. 
68.1 ± 12.7) plaque number (Figure 16C).  Plaque size in the two genotypes was  
indistinguishable: 1299 ± 123 vs. 1816 ± 100 and 1328 ± 294 vs. 1330 ± 179 μm2 in the 
cortex and hippocampus, respectively (Figure 16D).  Thus, reductions in plaque 
load/number in response to S100A1 ablation are age-independent. In summary, this is 
the first demonstration that S100A1 ablation non-selectively reduces plaque load/number 
without altering plaque size and suggests that S100A1 accelerates new plaque deposition 
in the AD brain.     
S100A1 ablation reduces gliosis in the PSAPP AD mouse model.  Astrocytosis (Li, et 
al., 2011) and microgliosis (Cameron and Landreth, 2010; Wyss-Coray and Mucke, 
2002) are early and critical events in the in the pathogenesis of AD (Eikelenboom, et al., 
2010; Heneka, et al., 2010; Lee, et al., 2010).  The astrocytic marker GFAP and 
microglial marker Iba1 were used to determine if S100A1 ablation also reduced gliosis.  
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In 6 month old PSAPP and PSAPP/S100A1-/- mice, cortical and hippocampal plaque-
associated GFAP staining was indistinguishable from previous reports:  GFAP-positive  
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Figure 16:  S100A1 ablation reduces cortical and hippocampal plaque load in twelve month old PSAPP mice.  
Panel A contains representative micrographs of parasagittal cortical/hippocampal sections from 12 month old 
PSAPP and  PSAPP/S100A1-/- mice stained with congo red (pink) and hematoxylin (blue) to visualize plaques 
and nuclei, respectively.  The histograms depict the mean congophilic plaque load (Panel B), plaque number 
(Panel C), and plaque size (Panel D) + SEM in PSAPP (solid red bars, n=8), and PSAPP/S100A1-/- (hatched red 
bars, n=4) mice.  Asterisks denote p0.05 when compared to the PSAPP group.
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cell bodies and processes (Figure 17A and B) (Mori, et al., 2006; Mori, et al., 2010).  
However, 6 month old PSAPP/S100A1-/- mice exhibited a 3.7 fold reduction in cortical 
(3.2940 ± 1.0174 vs. 12.1572 ± 0.8246 percent area) and 1.5 fold reduction in 
hippocampal (8.3168 ± 1.3755 vs. 12.0146 ± 0.7926 percent area) GFAP staining when 
compared to age-matched PSAPP mice (Figure 17C).  Twelve month old 
PSAPP/S100A1-/- mice exhibited a 2.3 fold reduction in cortical and (14.7362 ± 2.4743 
vs. 33.3435 ± 3.0363 percent area) and 2.4 fold reduction in hippocampal (12.7549 ± 
0.6016 vs. 30.8905 ± 2.8725 percent area) GFAP staining when compared to age-
matched PSAPP mice (Figure 17D).  Furthermore, there was there was a direct 
correlation between GFAP staining and plaque load (Pearson’s Correlation Coefficient 
0.9134 p < 0.0001) (Figure 17E).  Interestingly, S100A1 ablation did not alter GFAP 
staining in non-plaque containing areas such as the cerebellum (Figure 17A).  These data 
demonstrate that S100A1 ablation reduces astrocytosis as well as amyloidogenesis.  
The microglial marker Iba1 was used to determine if S100A1 ablation also reduced 
microgliosis. In 6 month old PSAPP and PSAPP/S100A1-/- mice, plaque associated Iba1 
positive microglia (somata and processes) were observed in the hippocampus and cortex 
(Figure 18A and B) and this staining pattern was indistinguishable from previous reports 
for AD mouse models  (Mori, et al., 2006; Mori, et al., 2010).  However, 
PSAPP/S100A1-/- mice exhibited a 1.6 fold reduction in cortical  (2.4590 ± 0.4860 vs. 
4.0259 ± 0.3222 percent area) and a  1.4 fold reduction in hippocampal (3.3849 ± 
0.0.2023 vs. 4.6109 ± 0.2560 percent area) Iba1 staining when compared to PSAPP mice 
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(Figure 18C).  Twelve month old PSAPP/S100A1-/- mice exhibited a 4 fold decrease in 
cortical (2.0854 ± 0.4076 vs. 8.5340 ± 0.4575) and a 2.9 fold decrease in  
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Figure 17: S100A1 ablation reduces astrocytosis. Representative photomicrographs of parasagittal 
cortical/hippocampal sections from 6 month old PSAPP and PSAPP/S100A1-/- mice are shown stained with a GFAP 
antibody which labels astrocytes (Panel A) and co-stained with GFAP and congo red, which labels fibrillar plaques, 
to demonstrate plaque associated astrocyte staining.  The histograms depict the mean GFAP positive area ± SEM in 
six (blue, Panel C) and twelve (red, Panel D) month old PSAPP (solid bars, n=8 at 6 months, n=6 at 12 months), and 
PSAPP/S100A1-/- ( hatched bars, n=4 at 6 months, n=3 at 12 months), mice.  Scale bars represent 50 microns and 
asterisks denote p0.05 when compared to the PSAPP group. Panel E is a scatter plot of the mean GFAP burden 
versus plaque load for each animal at six (blue) and twelve (red) months (cortex and hippocampus).
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hippocampal (2.4999 ± 0.3321 vs. 7.1809 ± 0.6252 percent area) Iba1 staining when 
compared to PSAPP mice (Figure 18D). Furthermore, there was a direct correlation  
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Figure 18: S100A1 ablation reduces microgliosis. Representative photomicrographs of parasagittal 
cortical/hippocampal sections from 6 month old PSAPP and PSAPP/S100A1-/- mice are shown stained with an Iba1 
antibody which labels microglia (Panel A) and co-stained with Iba1 and congo red, which labels fibrillar plaques, to 
demonstrate plaque associated microglial staining.  The histograms depict the mean Iba1 positive area ± SEM in six 
(Panel C) and twelve (Panel D) month old PSAPP (solid bars, n=8 at 6 months, n=6 at 12 months), and 
PSAPP/S100A1-/- ( hatched bars, n=4 at 6 months, n=3 at 12 months), mice.  Scale bars represent 50 microns and 
asterisks denote p0.05 when compared to the PSAPP group. Panel E is a scatter plot of the mean GFAP burden 
versus plaque load for each animal at six (blue) and twelve (red) months (cortex and hippocampus).
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between Iba1 staining and plaque load (Pearson’s Correlation Coefficient 0.9091            
p < 0.0001) (Figure 18E).   Finally, S100A1 ablation did not alter Iba1 staining in non-
plaque containing regions, such as the cerebellum (Figure 18A).  Collectively, these 
findings demonstrate that reductions in plaque load in response to S100A1 ablation 
directly correlate with reductions in inflammation (astrocytosis and microgliosis) and are 
the first report that S100A1 is pro-inflammatory. 
S100A1 and S100B ablation synergistically reduce plaque load and inflammation.  
Previous studies have demonstrated that another member of the S100 family, S100B, 
selectively reduces cortical, but not hippocampal, plaque load and inflammation (Roltsch 
et al., 2010).  Because S100A1 is expressed primarily in neurons, and S100B primarily 
in glial cells (Zimmer, et al., 2005), we hypothesize that the effect of concurrent 
ablation/inhibition of S100A1 and S100B on AD pathology would be synergistic. To test 
this hypothesis, plaque load, astrocytosis and microgliosis were quantified in 6 and 12 
month old PSAPP/S100A1/S100B double knockout mice.  There was 6.6 fold reduction 
in cortical and an 8.3 fold reduction in hippocampal plaque load in  
 
Table 2.  S100A1 and S100B ablation synergistically reduce plaque load and 
microgliosis in six month old PSAPP mice
PSAPP/S100A1-/-/S100B-/- PSAPP/S100A1-/- PSAPP
Plaque Load
(% Area)
Cortex 0.0254 ± 0.0086*# 0.0481 ± 0.0062* 0.1676 ± 0.0156
Hippocampus 0.0102 ± 0.0154*# 0.0351 ± 0.008* 0.0845 ± 0.0220
GFAP
(% Area)
Cortex 2.1424 ± 0.7378* 3.2940 ± 1.0174* 11.7507 ± 0.7088
Hippocampus 8.9700 ± 0.7378* 8.3168 ± 1.3755* 12.0146 ± 0.7926
Iba1
(%Area)
Cortex 1.1208 ± 0.1570*# 2.4590 ± 0.4860* 4.0259 ± 0.3222
Hippocampus 2.0010 ± 0.3306*# 3.3849 ± 0.2023* 4.6109 ± 0.2560
The table depicts the mean plaque load, GFAP burden and Iba1 burden ± SEM in six month old PSAPP, 
PSAPP/S100A1-/-, and PSAPP/S100A1-/-/S100B-/- mice. Asterisks denote p0.05 when compared to the 
PSAPP group and number sign denotes p<0.05 when compared to the PSAPP/S100A1-/- group. 
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PSAPP/S100A1-/-/S100B-/-  when compared to PSAPP mice and these reductions were 
significantly greater than the 2-4 fold reductions observed in PSAPP/S100A1-/- mice 
(Table 2).  These synergistic reductions in plaque load were associated with synergistic 
reductions in microgliosis but not astrocytosis. PSAPP/S100A1-/-/S100B-/- mice 
exhibited a 3.6 fold reduction in cortical and a 2.3 fold reduction in hippocampal Iba1 
staining, both of which were significantly greater than the reductions observed in 
PSAPP/S100A1-/- (Table 2). In contrast, GFAP staining in 6 month old PSAPP/S100A1-
/-/S100B-/- and PSAPP/S100A1-/- mice were indistinguishable (Table 2).   While direct 
comparisons with the previously published data for the PSAPP/S100B-/- line cannot be 
made, the fold reductions in plaque load (3-fold), Iba1 staining (4-fold) and GFAP 
staining (2-fold) in this study for the PSAPP/S100A1-/-/S100B-/- line are greater 
(Roltsch, et al., 2010) and support the conclusion that effects of S100A1 and S100B are 
synergistic.  However, this synergy was age- and region- specific. In 12 month old 
animals, only cortical GFAP staining exhibited a synergistic reduction in 
PSAPP/S100A1-/-/S100B-/- 
 
Table 3. S100A1 and S100B ablation synergistically reduce cortical astrocytosis 
in twelve month old PSAPP mice
PSAPP/S100A1-/-/S100B-/- PSAPP/S100A1-/- PSAPP
Plaque Load
(% Area)
Cortex 0.3401 ± 0.0490* 0.3212 ± 0.0257* 1.0023 ± 0.0354
Hippocampus 0.2353 ± 0.0492* 0.2478 ± 0.0414* 0.5511 ± 0.0684
GFAP
(% Area)
Cortex 8.9241 ± 2.3083*# 14.7363 ± 3.2256* 33.3435 ± 3.0363
Hippocampus 15.7444 ± 1.8148* 12.7549 ± 0.6016* 33.5349 ± 1.3751
Iba1
(%Area)
Cortex 0.9184 ± 0.2303* 2.0854 ± 0.4076* 8.5340 ± 0.4575
Hippocampus 1.6235 ± 0.6526* 2.5000 ± 0.3321* 7.1809 ± 0.6252
The table depicts the mean plaque load, GFAP burden and Iba1 burden ± SEM in twelve month old PSAPP, 
PSAPP/S100A1-/-, and PSAPP/S100A1-/-/S100B-/- mice. Asterisks denote p0.05 when compared to the 
PSAPP group and number sign denotes p<0.05 when compared to the PSAPP/S100A1-/- group. 
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mice (8.5 fold) when compared to PSAPP/S100A1-/- mice (2.3 fold) (Table 3).  
Comparison data at 12 months of age for the PSAPP/S100B-/- line is not available. 
Collectively, these data demonstrate that the synergistic effects of S100A1 and S100B 
ablation on AD histopathology are age-, region- and endpoint-specific and support the 
current view in the field that S100 family members exhibit partial functional/mechanistic 
redundancy.  
Discussion 
In summary, this is the first demonstration that S100A1 ablation reduces AD 
histopathology. The presence of detectable S100A1 staining, some of which was plaque-
associated, in PSAPP and human autopsy specimens is consistent with a detrimental gain 
of S100A1 function/signaling in AD in response to Ca2+ dysregulation. Six and twelve 
month old PSAPP/S100A1 knockout mice exhibited decreases in hippocampal and 
cortical plaque load/plaque number but not plaque size, suggesting that S100A1 
promotes the formation of new plaques.  Furthermore, there was a direct correlation 
between plaque load and inflammation, i.e.  microgliosis (Iba1 staining) and astrocytosis 
(GFAP staining).  Astrocytosis (Li, et al., 2011) and microgliosis (Cameron and 
Landreth, 2010; Wyss-Coray and Mucke, 2002)  are early and critical events in AD 
pathogenesis, (Eikelenboom, et al., 2010; Heneka, et al., 2010; Lee, et al., 2010) and 
could be the cause or result of reductions in plaque load.  Phenotypic characterization of 
the microglial and astrocytic populations in PSAPP/S100A1 knockout mice will provide 
important insights regarding the S100A1-regulated processes that contribute to AD as 
well as the relationship between plaques and inflammation.   The increased fold 
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reductions in plaque load and microgliosis in 12 versus 6 month old animals suggests 
that S100A1 ablation/inhibition will delay and reduce the formation of new plaques even 
if therapy is initiated after plaques are detected.  In addition, there is a strong probability 
that S100A1 may serve as a common upstream regulator of both tau 
phosphorylation/neurofibrillary tangles and Aβ production/plaque deposition (Small and 
Duff, 2008), since S100A1 regulates tau phosphorylation and microtubule stability 
(Baudier, et al., 1982; Zimmer, et al., 1998).  Finally, S100A1 ablation/inhibition has 
been reported to alter cognitive function in normal animals (Ackermann, et al., 2006; 
Kubista, et al., 1999; O'Dowd, et al., 1997) suggesting that S100A1 ablation/inhibition in 
AD will impact cognitive function.  Even though the contribution of plaques, tangles and 
inflammation to cognitive decline remains unresolved (Castellani, et al., 2009; Gorelick, 
2010; Nelson, et al., 2009; Serrano-Pozo, et al., 2011; Thind and Sabbagh, 2007), our 
observations suggest that pharmacological therapies targeting S100A1 may  beneficially 
reduce inflammation and delay plaque deposition in AD patients.    
The cellular and plaque-associated S100A1 staining in AD specimens suggests 
that both intracellular and extracellular S100A1 contribute to the phenotypic changes 
observed in PSAPP S100A1 knockout mice.  Upon binding Ca2+, S100 proteins undergo 
a conformational change which exposes a hydrophobic patch necessary for interacting 
with numerous intra- and extracellular protein targets and subsequent exertion of their 
biological effects (Zimmer, et al., 2003; Zimmer and Weber, 2010).  Inhibition of 
intracellular S100A1 signaling is predicted to increase dendrite formation/neurite 
extension; augment tubulin polymerization; decrease neuronal cell sensitivity to Aβ 
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toxicity; stimulate Akt phosphorylation and inhibit GSK3b-mediated tau 
phosphorylation, and normalize Ca2+ homeostasis (Zimmer, et al., 1998), all of which 
would reduce AD pathology.  These beneficial effects may be attributable to S100A1 
interaction with the Hsp70/Hsp90 multichaperone complex (Okada, et al., 2004),  
ryanodine receptor(Prosser, et al., 2008) SERCA pump (Green, et al., 2008; 
Vangheluwe, et al., 2005), tau (Baudier, et al., 1982), tubulin (Garbuglia, et al., 1999; 
Zimmer, et al., 1998) and/or p53 (Garbuglia, et al., 1999; van Dieck, et al., 2009). 
 Extracellular S100A1 could act in four ways: inhibition of S100A1-mediated 
cell death, autocrine/paracrine effects on surrounding cells, direct uptake into cells and 
subsequent modulation of intracellular events, and/or direct modulation of plaque 
deposition. Aβ exists as many distinct assemblies including monomers, low to high 
molecule weight oligomers, amyloid pores, protofibrils, and dense-core amyloid plaques 
(Glabe, 2008).   Extracellular S100A1 could promote fibril assembly by increasing the 
local concentrations of Ca2+ and/or other metals which predispose protofibrils to 
aggregation and fibril formation (Cherny, et al., 2001; Isaacs, et al., 2006; Opazo, et al., 
2003).  S100 proteins are substrates for the cross-linking transglutaminases (Ruse, et al., 
2001), which initiate Aβ oligomerization/aggregation, reduce clearance, and form 
assemblies responsible for cognitive loss (Atwood, et al., 2002; Hartley, et al., 2008).  
This interaction/modification may be one mechanism by which S100s enhance plaque 
deposition, decrease plaque clearance, and are retained in plaques.  Alternatively, 
extracellular S100A1 could promote plaque deposition via interaction with and 
regulation of one or more plaque associated proteins (Aβ peptides, ApoE, LDL receptor 
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related protein, proteoglycans, inflammatory molecules, serum-related molecules, 
proteases, and/or antioxidant defense proteins) (Costa, et al., 2004; Dolev and 
Michaelson, 2004; Eriksson, et al., 1995; Fraser, et al., 1993; Kinghorn, et al., 2006).  
S100s may also act by increasing Aβ transcytosis from the serum and/or decreasing Aβ 
clearance via interaction with RAGE, a member of the immunoglobulin-like cell surface 
receptor superfamily expressed on endothelial cells, neurons, and glia (Deane and 
Zlokovic, 2007; Hofmann, et al., 1999; Perrone, et al., 2008; Takeuchi and Yamagishi, 
2008; Yan, et al., 1996; Yan, et al., 2009).  RAGE is a multiligand receptor that binds 
members of the S100 family (Hofmann, et al., 1999; Perrone, et al., 2008) as well as Aβ 
(Takeuchi and Yamagishi, 2008).  Thus, paracrine/autocrine activation of RAGE 
receptor, by extracellular S100A1, could activate intracellular signaling pathways that 
ultimately result in increased Aβ levels. The development of effective pharmacological 
strategies for inhibiting S100A1 in patients will require quantifying the contribution of 
extracellular and intracellular forms of S100A1 as well as in vivo verification of the 
target proteins involved.  
 This is also the first report of in vivo synergism among S100 family members.  
Six month old PSAPP/S100A1-/-/S100B-/- exhibited synergistic reductions in plaque 
load/number, astrocytosis and microgliosis when compared to PSAPP/S100A1-/- (this 
study) and PSAPP/S100B-/- (Roltsch, et al., 2010) suggesting that these two S100 family 
members regulate different target proteins/cellular processes. These results were 
expected because these two family members are expressed in different cell types; 
S100A1 is expressed primarily in neurons and S100B is expressed in glia/microglia.  
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Interestingly, these synergistic effects were age-, region- and endpoint-specific.  This 
dynamic synergy may reflect changes in S100A1 and/or S100B levels, anatomical 
distribution, intracellular/extracellular ratios and/or subcellular distribution.  Regardless 
of mechanism, these findings confirm the partial functional/mechanistic redundancy 
among family members and observed in in vitro systems.   
Conclusions 
 Collectively, these data demonstrate that S100A1 ablation reduces plaque load, 
astrocytosis and microgliosis. The development of effective pharmacological strategies 
for modulating S100A1 function in patients will require quantifying the effects of 
S100A1 on cognitive function, delineating the contribution of extracellular vs. 
intracellular forms, identifying the S100A1-regulated target proteins/cellular processes 
in AD, and determining if changes in S100A1 expression/distribution are associated with 
particular stages/types of AD.  Since the synergistic effects of ablating S100A1 and 
S100B are not universal, the effects of inhibiting multiple family members must be 
systematically investigated. Finally, the beneficial effects of S100A1 ablation/inhibition 
may extend to other neurological disorders that involve dysregulation of neuronal cell 
Ca2+ homeostasis and/or inflammation.  
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CHAPTER IV 
PSAPP MICE EXHIBIT REDUCTIONS IN PLAQUE LOAD AND GLIOSIS IN 
RESPONSE TO S100A1/S100B INHIBITION WITH PASSIVE IMMUNOTHERAPY  
 
Background 
In the past decade, immunotherapy has emerged as a potential therapy for the 
treatment of AD (Citron, 2010; Delrieu, et al., 2011; Grill and Cummings, 2010; 
Solomon and Frenkel, 2010).  There are two possible strategies for treatment, active and 
passive immunotherapy.  Active immunotherapy is the administration of an antigen that 
stimulates an individual’s immune system to develop an adaptive immunity to the 
disease, allowing the body to destroy that specific antigen.  Passive immunotherapy is 
the administration of antigen specific antibodies that bind to extracellular forms of their 
antigen, rendering the antigen unable to interact with surrounding targets.  Since the 
prevailing theory of AD etiology and pathogenesis is the amyloid cascade hypothesis 
(Hardy and Allsop, 1991; Hardy and Higgins, 1992; Karran, et al., 2011), Aβ targeted 
therapies have dominated the field of active and passive immunotherapy (Morgan, 
2011).     
Early strategies for AD immunotherapy employed active immunotherapy.  In 
1999, the first Aβ immunotherapy was published by Schenk and his collaborators at Elan 
Pharmaceuticals in which they reported that treatment of an AD mouse model with a 
vaccine against Aβ prior to plaque formation was sufficient to block plaque formation as 
the mice aged (Morgan, 2011).  Since then, the development of novel immunotherapy 
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strategies has been a major focus of AD research.  Several studies reported that treatment 
with an Aβ vaccine not only cleared Aβ plaques, but also improved the cognitive deficit 
exhibited in both murine and non-human primate models of AD (Janus, et al., 2000; 
Kotilinek, et al., 2002; Lemere, et al., 2004; Morgan, 2011).  While studies of 
immunotherapy in animal models exhibited remarkable success and provided very 
promising results (Morgan, 2011), immunotherapy in human clinical trials resulted in a 
number of adverse side effects (Delrieu, et al., 2011).  Although initial phase I trials with 
a vaccine against the full length Aβ42 peptide produced no adverse results (Schenk, 
2002), a phase IIa trial with the vaccine was stopped prematurely after a subset (6%) of 
patients developed aseptic meningoencephalitis, an inflammation of the brain and 
meninges (Orgogozo, et al., 2003).  Upon further investigation, it was reported that Aβ42 
contains an epitope capable of activating T cells (Delrieu, et al., 2011; Monsonego and 
Weiner, 2003) and it was concluded that the meningoencephalitis response was an 
autoimmune reaction caused by the vaccine (Morgan, 2011; Orgogozo, et al., 2003).  
Although the study was interrupted, some patients did develop a significant antibody 
titer with no adverse effects, and the cognitive evaluations indicated less of a decline in 
cognition when compared to patients with no antibody titer, although these changes did 
not reach significance (Citron, 2010; Morgan, 2011).  In spite of these adverse effects of 
active immunization, the cognitive results suggest that an immunotherapy approach may 
be effect in treating AD (Morgan, 2011).   
Due to the adverse effects of active immunization, several companies have 
turned to passive immunotherapy.  In another phase II trial, passive immunotherapy with 
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bapineuzumab, a humanized Aβ antibody, resulted in 9.7% of patients developing 
vasogenic edema (Salloway, et al., 2009).  Vasogenic edema is caused by fluid leakage 
of the brain’s blood vessels into the parenchyma through a damaged blood brain barrier 
(Delrieu, et al., 2011).  Interestingly, the study reported a difference in response to the 
drug based on APOE ε4 carrier status, in that there was a potential treatment difference 
favoring bapineuzumab observed in noncarriers, while no difference was observed in 
APOE ε4 carriers (Salloway, et al., 2009).  A phase III study is now in progress with 
bapineuzumab (Grill and Cummings, 2010).  Currently there are five phase III trials 
being conducted for AD drug candidates, and three out of the five are passive 
immunotherapy trails utilizing a humanized monoclonal antibody to Aβ (Grill and 
Cummings, 2010).  Although, the lack of improvement in cognition in patient 
participating in recent clinical trials targeting Aβ emphasizes the need for additional 
targets (Boutajangout, et al., 2011; Holmes, et al., 2008).  Recent developments have 
also identified methods for earlier detection of AD, raising the possibility of early 
disease state and/or preventative treatments (Morgan, 2011).   
As demonstrated in the previous studies, S100A1/S100B ablation resulted in 
reductions of AD pathology in PSAPP mice (Chapters II and III) (Roltsch, et al., 2010).  
In addition to S100B’s increased expression in AD (Chaves, et al., 2010; Marshak, et al., 
1992; Roltsch, et al., 2010; Van Eldik and Griffin, 1994), numerous studies have 
reported that S100B regulates APP expression/processing, tau hyperphosphorylation and 
Aβ biogenesis, as well as being regulated by Aβ (Anderson, et al., 2009; Chow, et al., 
2010; Esposito, et al., 2008; Mori, et al., 2010).  Furthermore, S100A1 ablation in PC 12 
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cells results in an increased resistance to Aβ-induced cell death, stabilization of 
intracellular Ca2+ levels and a down-regulation of APP expression (Zimmer, et al., 
2005).   
These data validate S100A1 and S100B as novel drug targets for AD.  Because 
genetic ablation is not possible in the treatment of human diseases, this study uses 
passive immunotherapy to inhibit S100A1/S100B function in PSAPP mice.  Mice 
treated with anti-S100 from 3-6 months of age exhibited reductions in cortical and 
hippocampal plaque load as well as cortical astrocytosis.  In contrast, mice treated with 
anti-S100 from 6-9 months of age exhibited reductions in cortical, but not hippocampal, 
plaque load as well as cortical and hippocampal astrocytosis.  These results suggest that 
S100A1 and S100B act via different mechanisms in young mice.  In summary, this is the 
first report that pharmacological inhibition of S100A1/S100B is sufficient to reduce AD 
histopathology and that immunotherapy strategies which block S100A1/S100B function 
may be effective in treating AD in patients.      
Methods 
PSAPP mice.  The PSAPP double transgenic line was generated by crossing the Tg2576 
line (“Swedish” APPK670N/M671L mutation) with the 6.2 line (PS-1M146L) (Gordon, 
et al., 2001; Gordon, et al., 2002; Holcomb, et al., 1998; Holcomb, et al., 1999).  
Genotyping was performed as previously described (Gordon, et al., 2001).  All 
procedures involving animals were approved by the Texas A&M University Institutional 
Animal Care and Use Committee and comply with the NIH Guide for the Care and Use 
of Laboratory Animals. 
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Chronic immunotherapy treatment.  Cohorts of three and six month old PSAPP mice 
received bi-weekly 300μL intraperitoneal injections of a proprietary S100A1/S100B 
antibody made to the linker region of S100A1/S100B (Bethyl Laboratory Inc., 
Montgomery, TX), because the linker region exhibits the highest level of divergence, or 
IgG control (Bethyl Laboratory Inc.) at 1mg/mL for three months (6 injections total).  
Animals were sacrificed two weeks following the 12th injection (Figure 19).   
 
Months 3 5 71 2 4 6 8 9 10 11 12 13 14 15 16 17
Anti-S100 or IgG
10 mg/g
Figure 19: Timeline for anti-S100 immunotherapy treatment. Depicted above is the injection schedule for anti-
S100 therapy for each treatment/age group.  Red line denotes three month old treatment group and blue line denotes 
six month old treatment group.  Black arrows denote one 300µL injection of either anti-S100 or control IgG.  All 
animals received 6 bi-weekly injections and were sacrificed two weeks after the last injection.  
 
Sample acquisition/processing.  Brains were removed from anesthetized animals, 
rinsed in phosphate buffered saline (PBS) and sliced sagittally along the midline using 
an acrylic brain matrix (Ted Pella, Redding, CA).  One hemisphere was microdissected, 
removing the hippocampus (HP), cerebellum (CR), olfactory bulb (OLF), and slicing the 
cortex into two pieces, somatomotor (CX1) and visual (CX2), and snap frozen on dry 
ice.  The remaining hemisphere was fixed as previously described (Roltsch, et al., 2010).  
Briefly, brains were rinsed in phosphate buffered saline (PBS), fixed in 4% (wt/vol) 
paraformaldehyde in PBS for 30 minutes and sliced into 2 mm sagittal sections.  After a 
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second 30 minute fixation in 4% (wt/vol) paraformaldehyde in PBS, slices were 
permeablized and post-fixed in 10% buffered formalin for 16 hours.  Five micron 
sagittal sections of paraffin embedded sections were mounted on glass slides for 
subsequent staining.   
Immunofluorescent and Thioflavin S staining.  To minimize variability, sections from 
experimental and control groups were processed for plaque load and immunoreactivity 
together.  Consecutive slides (2/animal) each containing sections at Allen Brain Atlas 
Sagittal Levels 8 and 17 were depariffinized and rehydrated to distilled water. Thioflavin 
S was used to label fibrillar plaques, and slides were incubated in 0.5% (wt/vol) 
Thioflavin S (T1892, Sigma, St. Louis, MO) in 50% ethanol for 10 minutes followed by 
two 3 minute washes in 50% ethanol.  Slides will then be washed twice in distilled water 
for three minutes each and mounted with ProLong Gold antifade reagent with DAPI 
(P36935, Molecular Probes, Inc., Eugene, OR).  Immunostaining was performed on a 
DAKO autostainer (Dako, Carpentaria, CA) using a species specific AP polymer 
detection kit with the Warp Red chromogen kit (Warp Red, Biocare Medical, Walnut 
Creek, CA), which is highly fluorescent and visualized under a Texas Red filter, with 
conditions recommended by the primary antibody manufacturer.  Primary antibodies for 
immunohistochemistry included a rabbit polyclonal GFAP antibody (1-1000 dilution of 
Z0334, Dako). 
For quantification, digital images were captured, converted to gray scale, and 
positive pixels and total plaque load were quantified using Image J software (NIH 
Image, Bethesda, MD).  Plaque load and immunoreactivity were defined as the % area, 
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i.e. the area of positive pixels/total pixels X 100.  The data were expressed as the mean + 
SEM (n=4 for 3 and 6 month old Anti-S100 treated and n=3 for 3 and 6 month old IgG 
treated PSAPP mice).  An independent samples t-test (JMP by SAS, Cary, NC) was used 
to determine the significance (p<0.05) of measured differences between each of the 
treatment groups.  The Orthogonal Regression Correlation and scatter plots of the mean 
hippocampal and cortical GFAP staining/animal versus plaque load were used to 
determine the relationship between plaque load and astrocytosis/microgliosis. 
Results 
Anti-S100 therapy selectively reduces cortical and hippocampal plaque load in 
PSAPP mice.  To determine if anti-S100 therapy altered amyloidogenesis, plaque load 
was quantified in PSAPP mice treated with anti-S100 or IgG antibodies.  Thioflavin S 
positive plaques were observed in the cortex of six month old PSAPP mice treated with 
anti-S100 and IgG from three to six months of age (Figure 20).  Passive S100 
immunotherapy in 3-6 month old PSAPP mice resulted in a 4.4-fold reduction in cortical 
plaque load (0.0463 ± 0.0059 vs. 0.2050 ± 0.0413 percent area) with anti-S100 
treatment.  In addition, a 1.5-fold reduction in hippocampal plaque load (0.0560 ± 
0.0112 vs. 0.0862 ± 0.0082 percent area) was exhibited when anti-S100 and IgG treated 
PSAPP mice were compared.     
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Figure 20:  Anti-S100 therapy reduces cortical and hippocampal 
plaque load with treatment at 3-6 months of age.  Panel A contains 
representative micrographs of parasagittal cortical/hippocampal sections 
from 6 month old PSAPP mice treated with Anti-S100 and IgG from 
ages 3-6 months stained with Thioflavin S (green) and DAPI (blue) to 
visualize plaques and nuclei, respectively.  The histogram depicts the 
mean plaque load + SEM (Panel B) in PSAPP mice treated with Anti-
S100 (hatched bars, n=4), and control IgG (solid bars, n=3).  Asterisks 
denote p0.05 when compared to the control group.
*
 
 
 To determine if passive S100 immunotherapy reduces plaque load at a later stage 
of plaque deposition, plaque load was quantified in mice treated with anti-S100 or IgG 
from six to nine months of age.  As in the younger mice, Thioflavin S positive plaques 
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were observed in the cortex of both groups (Figure 21).  Passive S100 immunotherapy 
resulted in a 2.5-fold reduction in cortical plaque load (0.3894 ± 0.0720 vs. 0.9795 ± 
0.1804 percent area) when anti-S100 is compared to IgG.  Interestingly,  
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Figure 21: Anti-S100 therapy reduces cortical but not hippocampal 
plaque load with treatment at 6-9 months of age.  Panel A contains 
representative micrographs of parasagittal cortical/hippocampal sections 
from 9 month old PSAPP mice treated with Anti-S100 and IgG from 
ages 6-9 months stained with Thioflavin S (green) and DAPI (blue) to 
visualize plaques and nuclei, respectively.  The histogram depicts the 
mean plaque load + SEM (Panel B) in PSAPP mice treated with Anti-
S100 (hatched bars, n=4), and control IgG (solid bars, n=3).  Asterisks 
denote p0.05 when compared to the control group.
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there was no change in hippocampal plaque load (0.1748 ± 0.0469 vs. 0.3551 ± 0.1567 
percent area) when anti-S100 is compared to IgG (Figure 21B).  Thus, passive S100 
immunotherapy selectively reduces plaque load in PSAPP mice.   
Anti-S100 therapy selectively reduces astrocytosis in PSAPP mice.  Astrocytosis is 
an early and critical event in AD pathogenesis (Eikelenboom, et al., 2010; Heneka, et al., 
2010; Lee, et al., 2010; Li, et al., 2011).  The astrocytic marker GFAP was used to  
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Figure 22:  Anti-S100 therapy reduces cortical but not hippocampal astrocytosis with treatment at 3-6 months of 
age.  Panel A contains representative micrographs of parasagittal cortical/hippocampal sections from 6 month old 
PSAPP mice treated with Anti-S100 and IgG from ages 3-6 months stained with GFAP (red) and DAPI (blue) to 
visualize astrocytes and nuclei, respectively.  The histogram depicts the mean GFAP burden + SEM (Panel B) in 
PSAPP mice treated with Anti-S100 (hatched bars, n=4), and control IgG (solid bars, n=3). Panel C is a scatter plot 
of the mean GFAP burden versus plaque load for each animal (cortex only). Asterisks denote p0.05 when 
compared to the control group.
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determine if plaque reduction in response to passive S100 immunotherapy was 
accompanied by a decrease in astrocytosis.  Hippocampal and cortical GFAP positive 
astrocytes were observed in all ages of PSAPP mice from both treatment groups.  The 
GFAP staining was associated with cell bodies as well as long processes (Figure 22) and 
this pattern was indistinguishable from previous reports for AD models ((Mori, et al., 
2006; Mori, et al., 2010; Roltsch, et al., 2010).  Furthermore, passive S100 
immunotherapy in 3-6 month old PSAPP mice resulted in no change in hippocampal  
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Figure 23:  Anti-S100 therapy reduces cortical and hippocampal astrocytosis with   treatment at 6-9 months of 
age.  Panel A contains representative micrographs of parasagittal cortical/hippocampal sections from 9 month old 
PSAPP mice treated with Anti-S100 and IgG from ages 6-9 months stained with GFAP (red) and DAPI (blue) to 
visualize astrocytes and nuclei, respectively.  The histogram depicts the mean GFAP burden + SEM (Panel B) in 
PSAPP mice treated with Anti-S100 (hatched bars, n=4), and control IgG (solid bars, n=3). Panel C is a scatter plot 
of the mean GFAP burden versus plaque load for each animal (cortex and hippocampus). Asterisks denote p0.05 
when compared to the control group.
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GFAP staining (15.2834 ± 1.9726 vs. 18.9145 ± 3.6069 percent area) when anti-S100 
and IgG treated PSAPP mice were compared.  In contrast, immunotherapy resulted in a 
3.2-fold decrease in cortical GFAP staining (2.2877 ± 0.3881 vs. 7.3870 ± 1.1862 
percent area) when anti-S100- and IgG- treated groups were compared.  On the other 
hand, cortical and hippocampal decreases in astrocytosis were observed in PSAPP mice 
treated with passive S100 immunotherapy from 6-9 months of age.  GFAP staining in 
PSAPP mice was 2.3-fold less in the cortex (5.3442 ± 0.5948 vs. 12.1864 ± 1.5217 
percent area) and 1.8-fold less in the hippocampus (5.6562 ± 0.4907 vs. 9.9885 ± 0.6686 
percent area) when anti-S100- and IgG- treated groups were compared (Figure 23).  
Furthermore, in 3-6 and 6-9 month old mice there was a direct correlation between 
cortical GFAP staining and plaque load (Pearson’s Correlation Coefficient 0.8569 and 
0.8402 respectively, p < 0.0005) (Figure 22C and 23C).  Together these results 
demonstrate that decreased plaque load in response to passive S100 immunotherapy is 
accompanied by a regionally and temporally selective reduction in astrocytosis.   
Discussion 
This study definitively demonstrates that passive S100 immunotherapy reduces 
AD pathology.  In fact, PSAPP mice treated with anti-S100 from 3-6 months of age 
exhibited decreases in plaque load and cortical astrocytosis, while PSAPP mice treated 
with anti-S100 from 6-9 months of age exhibited reduced cortical, but not hippocampal 
plaque load with decreases in both cortical and hippocampal astrocytosis.  Furthermore, 
S100 ablation/inhibition has been reported to alter cognitive function in normal animals 
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(Ackermann, et al., 2006; Kubista, et al., 1999; O'Dowd, et al., 1997) suggesting that 
S100 ablation/inhibition in AD will impact cognitive function.   
  It is important to point out that passive S100 immunotherapy results statistically 
equivalent decrease in cortical but not hippocampal plaque load when anti-S100 
treatment from 3-6 month of age is compared to S100A1/S100B ablation at six months 
of age in PSAPP mice.  These differences are not attributable to effects from injection in 
that control IgG treatment does not increase cortical or hippocampal plaque load.  In 
addition, S100 immunotherapy also results in a statistically equivalent decrease in 
cortical GFAP staining when anti-S100 in 3-6 month is compared to S100A1/S100B 
ablation in 6 month old PSAPP mice.  The discrepancies between S100 ablation and 
immunotherapy as well as in regional efficacy suggest that S100A1 and S100B act via 
dynamic mechanisms in AD.   
This is the first report that passive S100 immunotherapy selectively reduces AD 
pathology.  As described in previous studies, S100A1 and S100B are plaque associated 
proteins in AD mouse models as well as human autopsy tissues (Figures 11 and 13) 
(Marshak, et al., 1992; Roltsch, et al., 2010; Van Eldik and Griffin, 1994; Van Eldik and 
Wainwright, 2003).  Given that common targets for immunotherapy in AD studies are 
plaque associated proteins, S100A1 and S100B represent two novel targets for 
immunotherapy treatment.  Collectively, these results suggest that passive S100 
immunotherapy combined with other approaches of S100 inhibition, such as small 
molecules, will effectively delay the progression of AD pathology.      
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Conclusions 
Collectively, these data definitively demonstrate that passive S100A1/S100B 
immunotherapy is reduces plaque load and astrocytosis in a regionally and temporally 
selective manner.  This study was the second approach that verifies the beneficial effects 
of S100A1/S100B inhibition.  Additional work is needed to determine if this reduction 
in histopathology will also decrease cognitive impairment exhibited in AD patients.  The 
inhibition of S100A1/S100B represent a novel treatment for AD and continued study of 
S100A1/S100B targets and mechanisms of action will aid in the development of 
effective therapeutic strategies for inhibiting S100A1/S100B function in AD treatment 
as well as other neurological disorders involving Ca2+ dysregulation.   
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CHAPTER V 
MiRNA EXPRESSION IS ALTERED IN RESPONSE TO S100A1/S100B MEDIATED 
REVERSAL OF AD PATHOLOGY 
 
Background   
Several neurodegenerative disorders are characterized by miRNA dysregulation, 
such as frontotemporal dementia, prion diseases, Parkinson’s disease, Huntington’s 
disease and Alzheimer’s disease (Enciu, et al., 2011; Fiore, et al., 2011; Hebert and De 
Strooper, 2007; 2009; Lau and de Strooper, 2010; Saugstad, 2010; Sonntag, 2010).  
MicroRNAs (miRNAs) are a family of small (~21-25 nucleotides) noncoding RNAs that 
can regulate gene expression at the post-transcriptional level (He and Hannon, 2004).  
There are currently 1424 human miRNAs and their sequences can be found on miR-Base 
website (http://www.mirbase.org/cgi-bin/mirna_summary.pl?org=hsa).  Most miRNAs 
are encoded within their own genes and clustered throughout the genome but a subset 
are encoded for within the introns of pre-mRNAs (Bartel, 2004).  Primary miRNA 
transcripts (pri-miRNAs) can be several thousand base pairs in length and are 
transcribed by RNA polymerase II or III in the nucleus (Lee, et al., 2004; Winter, et al., 
2009).  The pri-miRNA is then cleaved by the Drosha-DGCR8 complex and the 
precursor miRNA (pre-miRNA) is released, which is characterized by a stem and loop 
structure that is ~70 nucleotides in length.  The pre-miRNA is then exported to the 
cytoplasm by Exportin-5/Ran-GTP and cleaved by Dicer to generate the mature miRNA 
(Lau and de Strooper, 2010; Winter, et al., 2009).  Mature miRNAs function by 
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recognizing a specific sequence in an mRNA, called the seed region, binding to the 
mRNA and either triggering degradation or translational repression (Bartel, 2004; He 
and Hannon, 2004; Lim, et al., 2005).  Although mRNAs can, in principle, contain the 
miRNA “seed region” along their complete length, the most common site is within the 3’ 
untranslated region (UTR) (Ketting, 2010).  Recently, studies have indicated the 
involvement of deregulated miRNA expression in the pathogenesis of AD (Satoh, 2010).    
Most studies addressing the role of miRNAs in AD have focused on APP and 
BACE1 as targets of miRNAs (Delay and Hebert, 2011; Lau and de Strooper, 2010).  
Recent studies have shown that miR-107, -29a, -29b, -298 and -328 all target BACE1 
and miR-17-5p, -20a, -106a, -106b, -520c, -101, -16 and Let-7 all target APP of which 
miR-107, and miR-29b have been reported as dysregulated in AD (Delay and Hebert, 
2011; Hebert, et al., 2008; Lau and de Strooper, 2010; Wang, et al., 2008).  Several 
recent studies have been conducted using post-mortem brain tissues from AD patients 
and age-matched controls.  These studies have shown that a total of 22 miRNAs are 
dysregulated in the hippocampus, 67 miRNAs are dysregulated in the cortex, and 13 
miRNAs are dysregulated in the cerebellum of AD patients (Satoh, 2010).  
Unfortunately, the majority of these studies are human profiling studies and correlative 
in nature, they provide little proof of target gene regulation in vivo so the AD mouse 
models will provide a great tool for further dissecting the role of miRNA dysregulation 
in AD (Delay and Hebert, 2011).   
 Interestingly, miRNAs have also been implicated in S100 signaling and S100 
protein expression (Baudry, et al., 2010; Maru, et al., 2009; Shanmugam, et al., 2008).  
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Recent studies have shown that S100B binding to the RAGE receptor increases 
Cyclooxygenase-2 (COX-2) expression and stabilizes COX-2 mRNA (Shanmugam, et 
al., 2003).  Moreover, continued studies demonstrated that S100B significantly decreases 
miR-16 expression in monocytes which, in turn, blocks the degradation of the 
inflammatory gene product, COX-2 mRNA (Shanmugam, et al., 2008).  Additionally, 
S100A9 has been shown as a target for miR-196a in the progression of esophageal 
cancer (Maru, et al., 2009).  Together these data suggest that miRNAs are involve in 
S100 signaling/expression.   
In the previous chapters, we have shown that pharmacological inhibition and 
ablation of S100A1 and/or S100B significantly reduces AD pathology in the PSAPP 
mouse (Roltsch, et al., 2010).  This study examines the role of miRNAs in S100-
mediated reversal of pathology.  The expression of 15 miRNAs was altered in the 
hippocampus of 3 month old PSAPP mice.  The expression of 14 out of the 15 altered 
miRNAs was normalized in response to S100A1/S100B ablation in the PSAPP mice.  
These results suggest that miRNAs are involved in S100A1/S100B contributions to AD 
pathology and that these miRNAs may be novel therapeutic targets for effectively 
treating AD. 
Methods 
PSAPP X S100 knockout mice.  The PSAPP double transgenic line was generated by 
crossing the Tg2576 line (“Swedish” APPK670N/M671L mutation) with the 6.2 line (PS-
1M146L) (Gordon, et al., 2001; Gordon, et al., 2002; Holcomb, et al., 1998; Holcomb, et 
al., 1999).  The PSAPP/S100A1-/-/S100B-/- line was generated by crossing PSAPP 
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double transgenic males with S100A1-/-/S100B-/- knockout females and subsequent 
interbreeding of the heterozygous offspring (PSAPP/S100A1+/-/S100B+/- X 
PSAPP/S100A1+/-/S100B+/-).  To control for genetic background, all experiments used 
PSAPP/S100A1+/+/S100B+/+ and PSAPP/S100A1-/-/S100B-/-littermates.  Genotyping was 
performed as previously described (Gordon, et al., 2001; Prosser, et al., 2008; Roltsch, et 
al., 2010).  All procedures involving animals were approved by the Texas A&M 
University Institutional Animal Care and Use Committee and comply with the NIH 
Guide for the Care and Use of Laboratory Animals. 
MiRNA profiling.  Total RNA was isolated from snap frozen hippocampal tissue of 
PSAPP, PSAPP double knockout and nontransgenic control mice using the MirVana 
miRNA Isolation Kit (AM1560, Ambion, Foster City, CA).  MiRNA expression 
profiling was performed by Exiqon (Woburn, MA).  After quality verification, control 
and experimental total RNAs will be labeled with Cy3 and Cy5 respectively, hybridized 
to miRCURY ™ LNA microRNAs, and the data analyzed using the manufacturers 
protocol.   
Post-array validation.  MiRNAs that exhibited greatest statistically significant changes 
in expression were subjected to post-array validation using RT-PCR.  RT reactions were 
performed using the miRCURY LNA ™ Universal RT microRNA PCR Universal 
cDNA Synthesis kit (Exiqon) and the transcribed cDNA was then used for subsequent 
PCR amplification.  The SYBR Green Universal Master Mix (Exiqon) and miRCURY 
LNA ™ Universal PCR Primer sets were utilized and reactions run on a MyiQ RT-PCR 
Detection System (Bio-Rad Laboratory, Hercules, CA), which was optimized for 
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amplification of small RNAs.  All reactions were performed in triplicate and relative 
expression normalized against endogenous controls using the comparative delta-delta CT 
method.  An independent samples t-test (JMP, Cary, NC) was used to determine the 
significance of measured differences between the genotypes.     
Bioinformatic searches.  Each miRNA exhibiting a significant change of expression in 
both the microarray and post-array validation was subjected to bioinformatics searches 
for putative target genes (miRWalk) and biological processes (DAVID).  MiRWalk is a 
database of predicted and validated miRNA targets.  Searches performed on miRWalk 
use the miRWalk algorithm on the complete sequence of all know human, mouse and rat 
genes, as well as information from 8 other established miRNA prediction programs 
(RNA22, miRanda, miRDB, TargetScan, RNAhybrid, PITA, PICTAR, and Diana-
microT) on the 3’ UTRs of all known human, mouse and rat genes (http://www.ma.uni-
heidelberg.de/apps/zmf/mirwalk/).  The generated lists of target genes were then 
analyzed for pathway enrichment using DAVID (Database for Annotation, 
Visualization, and Interrogated Discovery) bioinformatics database.         
Results 
S100A1/S100B ablation normalizes miRNA expression.  To identify miRNA’s that 
may play a role in S100A1/S100B mediated reversal of AD pathology we first 
characterized the expression pattern of miRNA’s in the hippocampus of three month old 
PSAPP, and nontransgenic control mice.  The microarray analysis demonstrated that 15 
miRNAs were overexpressed in the hippocampus of 3 month old PSAPP mice, including 
miR-206, miR-34a, miR-195, miR-133a, miR-204, miR-1, miR-10b, miR-133b, miR-
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194, miR-34c, miR-192, miR-320, miR-96, miR-486 and miR-448 (Figure 24).  
Furthermore, all of these miRNAs exhibited overexpression in the PSAPP model.   
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Figure 24.  S100A1 and S100B ablation normalize miRNA expression profile.  Histogram depicts expression of 
significantly dysregulated miRNAs in 3 month old hippocampus from PSAPP/S100A1-/-/S100B-/- (    ) and non-
transgenic (    ) when compared to PSAPP (    ).  Means were corrected for nonbiological background contribution 
and normalized using the LOESS method.  miRNAs that passed the filtering criteria (>2 fold change in 
expression) are expressed as the fold change + the SD (n=3) when compared to PSAPP levels. 
 
 
 Additional studies were then completed to determine the miRNA expression 
profile in response to S100A1/S100B-mediated changes in AD pathology.  The 
expression of 14 out of the 15 altered miRNAs in PSAPP mice were normalized in 
response to S100A1/S100B ablation in the hippocampus of 3 month old PSAPP mice.  
Further examination using qRT-PCR to validate the microarray results were confined to 
seven miRNAs (miR-206, miR-34a, miR-34c, miR-195, miR-133a, miR-204, miR-1 and 
miR-448) exhibiting the greatest decrease in expression in the PSAPP/S100A1-/-/S100B-
/- mice.  We used miR-124 as an endogenous control to normalize expression which was 
uniformly expressed within each treatment and highly expressed across all treatment 
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groups.  Five miRNAs exhibited a significant change in expression in the 
PSAPP/S100A1-/-/S100B-/- mice when compared to PSAPP mice, miR-448, miR-133a, 
miR-204 and miR-206 one miR-34a (Figure 25).  Interestingly, only one of the identified 
miRNAs (miR-34a) has been previously reported in AD (De Smaele, et al., 2010; Delay 
and Hebert, 2011; Provost, 2010; Satoh, 2010).   
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Figure 25.  RT-PCR Validation of altered miRNAs.  Histogram depicts fold change of miRNA expression in 
hippocapmus of three month old PSAPP/S100A1-/-/S100B-/- (    , n=6) and non-transgenic (     , n=6) when 
compared to PSAPP (    , n=9).  Expression was normalized to miR-124 and expressed as fold change ± SEM 
relative to PSAPP levels.
 
 
Functional analysis of miRNA target genes/pathways.  Since miRNAs are thought to 
regulate target gene expression and pathways it was important to look at the predicted 
target genes and pathways of the five validated miRNAs.  In order to determine the  
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miRNA
Total
Targets*
Assigned
Targets* KEGG Pathway#
Number of 
Genes# Percent# P-value# Benjamini#
448 498 5 No significant pathways -- -- -- --
204 818 38 Pathways in cancer 8 21.1 7.50E-05 3.40E-03
Pancreatic cancer 5 13.2 9.70E-05 2.20E-03
Chronic myeloid leukemia 5 13.2 1.10E-04 1.70E-03
Bladder cancer 4 10.5 3.90E-04 4.40E-03
Colorectal cancer 4 10.5 3.00E-03 2.60E-02
Prostate cancer 4 10.5 3.50E-03 2.60E-02
133a 418 133 Pathways in cancer 16 15.4 2.10E-07 2.10E-05
Colorectal cancer 8 7.7 1.30E-05 6.40E-04
MAPK signaling pathway 10 9.6 8.50E-04 2.80E-02
TGF-beta signaling pathway 6 5.8 1.40E-03 3.40E-02
Endometrial cancer 5 4.8 1.50E-03 2.90E-02
Prostate cancer 6 5.8 1.50E-03 2.50E-02
Acute myeloid leukemia 5 4.8 2.20E-03 3.10E-02
Focal adhesion 8 7.7 2.80E-03 3.50E-02
206 567 126 Pancreatic cancer 9 9.8 1.80E-07 1.60E-05
Pathways in cancer 15 16.3 5.90E-07 2.50E-05
MAPK signaling pathway 12 13 1.80E-05 5.00E-04
Focal adhesion 10 10.9 6.10E-05 1.30E-03
Colorectal cancer 7 7.6 9.40E-05 1.60E-03
Amyotrophic lateral 
sclerosis (ALS) 6 6.5 1.00E-04 1.40E-03
Epithelial cell signaling in 
Helicobacter pylori infection 6 6.5 3.30E-04 4.00E-03
Bladder cancer 5 5.4 5.10E-04 5.40E-03
Chronic myeloid leukemia 6 6.5 5.20E-04 4.90E-03
Adherens junction 6 6.5 5.90E-04 5.00E-03
Notch signaling pathway 5 5.4 7.90E-04 6.10E-03
Non-small cell lung cancer 5 5.4 1.30E-03 9.40E-03
Dorso-ventral axis 
formation 4 4.3 1.40E-03 9.00E-03
Renal cell carcinoma 5 5.4 3.50E-03 2.10E-02
Melanoma 5 5.4 3.70E-03 2.10E-02
Neurotrophin signaling 
pathway 6 6.5 4.90E-03 2.60E-02
TGF-beta signaling pathway 5 5.4 7.50E-03 3.70E-02
ErbB signaling pathway 5 5.4 7.50E-03 3.70E-02
Apoptosis 5 5.4 7.50E-03 3.70E-02
Cytokine-cytokine receptor 
interaction 8 8.7 8.50E-03 3.90E-02
Endometrial cancer 4 4.3 1.10E-02 4.90E-02
Table 4.  Target and pathway predictions for miRs -448, -204, -133a and -206
*miRWalk (http://www.ma.uni-heidelberg.de/apps/zmf/mirwalk/
#DAVID (http://david.abcc.ncifcrf.gov/  
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functional significance of these miRNA expression changes, validated target genes were 
obtained from miRWALK (http://www.ma.uni-heidelberg.de/apps/zmf/mirwalk/, 
August 8, 2011).  The validated target gene lists were then analyzed for each individual 
miRNA and all miRNAs together using the DAVID Bioinformatics Resources for 
functional annotation.  Functional analysis suggests that miR-204, miR-133a and miR-
206 are highly involved in several cancer pathways, while miR-206 is also involved in 
focal adhesion and MAPK signaling pathways.  In contrast, miR-448 was not reported to 
significantly regulate any KEGG pathway (Table 4).  Additionally, Mir-34a was the only 
miRNA that exhibited an up-regulation in the PSAPP/S100A1-/-/S100B-/- mice and 
similar to the other three miRNAs that were predicted to regulate pathways, functional 
analysis suggested that miR-34a is highly involved in multiple cancer pathways.  In 
addition, it is predicted to be involved in the cell cycle, p53 signaling pathway and 
apoptosis (Table 5).   
Finally, when the validated target genes of all five miRNAs are grouped together, 
functional annotation further implicates these miRNAs in multiple cancer pathways such 
as leukemia, prostate and pancreatic cancers as well as melanoma.  In addition, the five 
altered miRNAs were also implicated in cell cycle pathways, the p53 signaling pathway 
and apoptosis (Table 6).  While these results may seem unexpected, but the fact that 
these studies were completed in a very early time point in AD pathogenesis  and 
knowing that S100s are involved in stress related pathways, these results are not all 
together unexpected.               
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miRNA
Total
Targets*
Assigned
Targets* KEGG Pathway#
Number of 
Genes# Percent# P-value# Benjamini#
34a 600 104 Pathways in cancer 35 19.6 4.80E-17 5.20E-15
Chronic myeloid leukemia 18 10.1 2.40E-14 1.30E-12
Melanoma 17 9.5 1.60E-13 5.90E-12
Prostate cancer 18 10.1 4.90E-13 1.30E-11
Glioma 15 8.4 7.50E-12 1.60E-10
Bladder cancer 13 7.3 1.00E-11 1.80E-10
Small cell lung cancer 15 8.4 4.60E-10 7.00E-09
Pancreatic cancer 14 7.8 7.10E-10 9.50E-09
Cell cycle 17 9.5 1.40E-09 1.60E-08
Non-small cell lung cancer 12 6.7 4.20E-09 4.40E-08
p53 signaling pathway 13 7.3 4.50E-09 4.30E-08
Endometrial cancer 11 6.1 4.00E-08 3.50E-07
Colorectal cancer 13 7.3 5.40E-08 4.40E-07
Acute myeloid leukemia 10 5.6 1.30E-06 1.00E-05
Thyroid cancer 7 3.9 1.50E-05 1.10E-04
Neurotrophin signaling 
pathway 12 6.7 2.40E-05 1.60E-04
Focal adhesion 14 7.8 1.20E-04 7.50E-04
Wnt signaling pathway 11 6.1 6.40E-04 3.80E-03
T cell receptor signaling 
pathway 9 5 1.10E-03 6.20E-03
Apoptosis 8 4.5 1.40E-03 7.50E-03
ErbB signaling pathway 8 4.5 1.40E-03 7.50E-03
Renal cell carcinoma 7 3.9 2.20E-03 1.10E-02
Jak-STAT signaling pathway 10 5.6 3.00E-03 1.40E-02
VEGF signaling pathway 7 3.9 3.20E-03 1.50E-02
Toll-like receptor signaling 
pathway 8 4.5 3.30E-03 1.50E-02
Progesterone-mediated 
oocyte maturation 7 3.9 6.30E-03 2.70E-02
Adipocytokine signaling 
pathway 6 3.4 9.40E-03 3.80E-02
Notch signaling pathway 5 2.8 1.30E-02 4.90E-02
Table 5.  Target and pathway predictions for miR-34a
*miRWalk (http://www.ma.uni-heidelberg.de/apps/zmf/mirwalk/
#DAVID (http://david.abcc.ncifcrf.gov/                     
 
Discussion 
In this study, we identified five candidate miRNAs that are differentially 
regulated in response to S100 mediated reversal of AD pathology and definitively 
demonstrate that miRNAs are involved in S100-mediated reversal of AD pathology.  In 
addition, the pathways that these five validated miRNAs are predicted to regulate appear 
 81
miRNA
Total
Targets*
Assigned
Targets* KEGG Pathway#
Number of 
Genes# Percent# P-value# Benjamini#
All 3061 424 Pathways in cancer 52 15.4 3.80E-22 4.90E-20
Chronic myeloid leukemia 24 7.1 6.40E-17 7.10E-15
Pancreatic cancer 23 6.8 3.50E-16 1.40E-14
Prostate cancer 22 6.5 5.40E-13 1.80E-11
Melanoma 20 5.9 6.40E-13 1.70E-11
Colorectal cancer 21 6.2 1.70E-12 3.60E-11
Bladder cancer 16 4.7 1.80E-12 3.30E-11
Glioma 18 5.3 9.80E-12 1.60E-10
Non-small cell lung cancer 15 4.4 1.30E-09 1.90E-08
Endometrial cancer 14 4.1 8.40E-09 1.10E-07
Cell cycle 20 5.9 2.10E-08 2.50E-07
Small cell lung cancer 16 4.7 7.80E-08 8.40E-07
MAPK signaling pathway 28 8.3 1.50E-07 1.50E-06
p53 signaling pathway 14 4.1 2.60E-07 2.40E-06
Focal adhesion 22 6.5 2.50E-06 2.20E-05
Neurotrophin signaling 
pathway 17 5 2.80E-06 2.30E-05
Acute myeloid leukemia 11 3.3 1.70E-05 1.30E-04
TGF-beta signaling 
pathway 13 3.8 2.60E-05 1.90E-04
Adherens junction 12 3.6 4.10E-05 2.80E-04
T cell receptor signaling 
pathway 14 4.1 5.30E-05 3.40E-04
Apoptosis 12 3.6 1.30E-04 8.00E-04
Wnt signaling pathway 16 4.7 1.30E-04 7.90E-04
Thyroid cancer 7 2.1 3.20E-04 1.80E-03
Adipocytokine signaling 
pathway 10 3 3.40E-04 1.80E-03
Cytokine-cytokine receptor 
interaction 21 6.2 4.00E-04 2.10E-03
Renal cell carcinoma 10 3 4.70E-04 2.40E-03
ErbB signaling pathway 11 3.3 5.80E-04 2.80E-03
Notch signaling pathway 8 2.4 8.40E-04 3.90E-03
Dorso-ventral axis 
formation 6 1.8 1.20E-03 5.40E-03
Amyotrophic lateral 
sclerosis (ALS) 8 2.4 1.70E-03 7.40E-03
Epithelial cell signaling in 
Helicobacter pylori infection 9 2.7 1.80E-03 7.30E-03
VEGF signaling pathway 9 2.7 3.30E-03 1.30E-02
Type II diabetes mellitus 7 2.1 4.40E-03 1.70E-02
Insulin signaling pathway 12 3.6 5.20E-03 2.00E-02
Jak-STAT signaling 
pathway 13 3.8 5.40E-03 2.00E-02
Toll-like receptor signaling 
pathway 10 3 6.30E-03 2.20E-02
B cell receptor signaling 
pathway 8 2.4 1.20E-02 4.20E-02
Table 6.  Target and pathway predictions for all validated miRNAs
*miRWalk (http://www.ma.uni-heidelberg.de/apps/zmf/mirwalk/
#DAVID (http://david.abcc.ncifcrf.gov/
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to be related to previously reported S100 functions.  Interestingly, out of the five 
validated miRNAs, only miR-34a has been previously identified in AD (Wang, et al., 
2009).  Wang, et al. (2009) reported that miR-34a was up-regulated in their double 
transgenic AD mouse model when compared to nontransgenic mice.  In contrast, we 
found that miR-34a was not up-regulated in the PSAPP AD mouse model, but was up-
regulated in response to S100A1/S100B ablation.  A possible reason for this discrepancy 
is the brain region used in the studies.  Wang, et al. (2009) conducted their studies in the 
cortex while this study was conducted in the hippocampus of 3 month old mice.   
MiR-34a is a member of the miR-34 family and, in mice, is expressed throughout 
most tissue types with highest expression in the brain (Aranha, et al., 2011).  It has been 
suggested that miR-34a possesses cell cycle regulatory potential and anti-proliferative 
capacity through p53 dependent and independent mechanisms (Chang, et al., 2007; He, 
et al., 2007; Tarasov, et al., 2007).  In fact, miR-34a is a direct transcriptional target of 
p53 which positively regulates miR-34a expression (He, et al., 2007; Raver-Shapira, et 
al., 2007; Tarasov, et al., 2007).  Increased expression of miR-34a has also been reported 
to induce cell cycle arrest in G1 by inhibiting G1/S phase transition through negative 
regulation of cyclin D1 (CCDN1) and cyclin dependent kinase 6 (CDK6) (Sun, et al., 
2008; Tarasov, et al., 2007).    Furthermore, p63 also directly targets, and represses miR-
34a expression, which has been shown to restore cell cycle progression and expression 
of CCND1 and CDK6 (Antonini, et al., 2010).  Interestingly, it has been suggested that 
aberrant cell cycle re-entry by mature neurons leads to the apoptotic neuronal loss 
exhibited in AD (Lopes, et al., 2009). Collectively, these studies implicate miR-34a in 
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apoptosis and cell cycle progression/inhibition suggesting that miR-34a represents a 
possible target for inhibiting the aberrant cell cycle re-entry of neurons as seen in AD.   
Additionally, we found that miR-448 was down regulated in response to 
S100A1/S100B ablation in PSAPP mice.  Interestingly, our bioinformatics searches 
were unable to identify any significant KEGG pathway predictions and only five 
validated gene targets for miR-448 (Table 4).  MiR-448 is located within the fourth 
intron of the Serotonin receptor 2C (Htr2c) and recent reports have suggested that miR-
448 regulates adipocyte differentiation through translational repression of Kruppel-like 
Factor 5 (KLF5), a known transcription factor that induces adipocyte differentiation 
(Kinoshita, et al., 2010; Millan, 2011).  In addition, NF-κB has been reported to suppress 
miR-448 expression in breast tumors undergoing chemotherapy-induced epithelial-
mesenchymal transition (Li, et al., 2011).  Recent studies have also suggested that 
interferon beta (IFNβ) upregulates miR-448 which directly targets the genomic RNA of 
the hepatitis C virus (HCV) and is capable of inhibiting HCV infection and replication 
(Pedersen, et al., 2007).  Furthermore, miR-448 was also identified in bovine alveolar 
macrophages (Xu, et al., 2009).  Together, these studies implicate miR-448 both cell 
differentiation and immune response (Pedersen and David, 2008; Xu, et al., 2009) 
suggesting it may have a role in the detrimental inflammation in the brain of AD 
patients.   
 We also observed a decrease in miR-204 expression in response to 
S100A1/S100B ablation in PSAPP mice.  A recent study characterized miR-204 as 
significantly enriched in the distal axons of primary sympathetic neurons when 
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compared to cell bodies (Natera-Naranjo, et al., 2010).  MiR-204 was also reported to be 
expressed in multiple structures of the human fetal eye, including the retina, lens and 
ciliary body as well as being the most highly expressed miRNA (with miR-211) in the 
retinal pigment epithelium (Wang, et al., 2010).  Multiple studies have suggested that 
miR-204 in an important factor in epithelial differentiation, but miR-204 has also been 
reported to be involved in the differentiation of other cell types such as mesenchymal 
stem cells, bone marrow stromal cells and mouse embryonic stem cells (Conte, et al., 
2010; Huang, et al., 2010; Saunders, et al., 2010).  In addition, miR-204 has been 
reported to suppress SIRT1 during mESC differentiation and maintain the low levels in 
adult tissues (Saunders, et al., 2010).  Interestingly, SIRT1 activation is reported to be 
beneficial in neurodegeneration.  In fact, SIRT1 activators have been shown to slow in 
vitro cell death and in vivo neurodegeneration as well as lead to anti-inflammatory 
activity by suppressing NF-κB activity  (Lavu, et al., 2008).  SIRT1 also deactivates p53 
and p73 through deacetylation, effectively controlling the transcriptional activities of, 
and apoptosis induced by p53 and p73 (Dai, et al., 2007; Vaziri, et al., 2001).  Increased 
miR-204 has also been reported to also regulate apoptosis and cell death due to oxidative 
and ER stress as well as a decrease in the expression of inflammatory factors (Li, et al., 
2011) as well as regulating autophagy (Xiao, et al., 2011).  Collectively, these studies 
suggest that miR-204 has a role in cell differentiation and p53 pathways as well as 
inflammation.   
Finally, we also saw a decrease of expression in two muscle specific miRNAs, 
miR-133a and miR-206.  Interestingly, neither of these miRNA’s has been previously 
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studied in the brain.  In fact, miR-206 has been reported as a skeletal muscle-specific 
miRNA (McCarthy, 2008).  Interestingly, as in the other miRNAs, miR-206 and miR-
133a are involved in human muscle cell differentiation (Koutsoulidou, et al., 2011).  
TGF-β targets both miR-206 and miR-133a, but miR-206 overexpression in vitro is 
reported to promote myogenic differentiation, while miR-133a overexpression enhances 
myoblast proliferation and represses differentiation (Dey, et al., 2011; Koutsoulidou, et 
al., 2011; Townley-Tilson, et al., 2010; Winbanks, et al., 2011).  MyoD is a transcription 
factor that regulates the transcription of miR-206 and miR-MyoD also acts as a 
proapoptotic factor by negatively regulating Pax3 expression through translational 
activation of miR-206 (Hirai, et al., 2010).  This regulation of Pax3/7 also regulated 
proliferation, differentiation and apoptosis in adult muscle stem cells (Chen, et al., 2010; 
Goljanek-Whysall, et al., 2011; Hirai, et al., 2010).  In addition, in renal cell carcinoma 
maxillary sinus squamous cell carcinoma, and bladder cancer, miR-133a targets 
TAGLN2, and increased expression inhibits proliferation and invasion, as well as 
increases cell cycle arrest and apoptosis (Kawakami, et al., 2011; Nohata, et al., 2011; 
Yoshino, et al., 2011).  In addition to TAGLN2, miR-133a also targets GSTP1 in bladder 
cancer inducing apoptosis (Uchida, et al., 2011).  While they have been studied in 
different tissue types, miR-206 and miR-133a exhibit apoptotic, proliferative and cell 
cycle regulative properties suggesting they may have a role in the neuronal cell death 
and aberrant cell cycle re-entry exhibited in AD pathology.          
 
 
 86
Conclusions 
Collectively, these data suggest that a specific subset of miRNAs contribute to 
the S100-mediated reversal of AD pathobiology in the PSAPP mouse model.  
PSAPP/S100A1-/-/S100B-/- mice exhibited a significant decrease in the expression of 
four miRNAs (miR-448, miR-133a, miR-204 and miR-206), and a significant increase in 
the expression of one, miR-34a.  Interestingly, the common predicted pathways for these 
miRNAs are cancer related suggesting that cancer and AD share some disease pathways.  
These alterations provide evidence that miRNA expression/inhibition is involved in 
S100A1/S100B-mediated reversal of histopathology in AD and provide novel targets for 
therapeutic intervention.  Finally, the beneficial effects of inhibiting S100A1/S100B, 
including miRNA expression/inhibition, may extend to other neurological diseases 
involving disruptions in cell cycle, p53 and/or differentiation.   
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CHAPTER VI 
CONCLUSIONS 
 
 Collectively, these data demonstrate that S100A1 and S100B inhibition 
represents a novel avenue for AD therapy.  This study used two different approaches to 
show that S100A1/S100B inhibition reduces plaque load and inflammation in the 
PSAPP mouse model of AD.  We demonstrated that S100A1 and/or S100B ablation 
synergistically reduces plaque load, astrocytosis and microgliosis.  Additionally, this 
S100-mediated reduction in pathology involves changes in miRNA expression.  
Furthermore, passive S100 immunotherapy mimics the results of ablation in cortical 
plaque load and astrocytosis.  These studies illustrate that the net effect of 
S100A1/S100B inhibition in AD is a reduction in histopathology, suggesting that 
S100A1 and S100B are involved in the onset/progression of AD pathology in patients.  
An early event in AD pathology is the destabilization of Ca2+ homeostasis, which causes 
an alteration in S100 signaling and detrimental gain of function that promotes AD 
pathology.  We hypothesize that S100A1 and S100B are involved in a p53 stress 
response pathway that contributes to the onset and progression of AD pathology (Figure 
26).  Although S100A1/S100B inhibition did not halt AD pathology all together, these 
studies suggest that this inhibition significantly slows the disease progression and it is 
predicted that slowing the progression of AD by as little as one year will reduce health 
care costs by $250 billion per year (Alzheimer’s Association, et al., 2011).  
Unfortunately, the only current treatments for AD “temporarily slow worsening of 
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symptoms for about six to 12 months, on average, for about half the individuals that take 
them” (Alzheimer’s Association, et al., 2011).  The results of this study suggest that the   
 
Figure 26.  S100A1 and S100B in AD. Above model describes possible mechanisms of S100A1/S100B
mediated increases in AD pathology.  Solid line denotes known events and dotted line denotes hypothesized 
pathways.
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inhibition of S100A1/S100B function through a combination of multiple approaches 
(passive immunotherapy, small molecule inhibitors, etc.) will significantly delay the 
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progression of AD pathology as well as improve cognitive decline in patients and 
perhaps aid in the treatment of other neurological diseases that involve the dysregulation 
of Ca2+ homeostasis as well.     
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